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ABSTRACT 
 
An increased prevalence of Pneumocystis jirovecii with point mutations in the fas 
gene, coding for dihydropteroate synthase (DHPS), has been associated with 
sulfonamide use. The purpose of this research was to investigate the prevalence of 
P. jirovecii strains containing DHPS polymorphisms in South Africa, and to 
ascertain their clinical relevance in HIV-positive patients with Pneumocystis 
pneumonia (PCP). A pilot study confirmed the presence of DHPS polymorphisms 
in 42% of specimens. A subsequent prevalence study confirmed the high 
prevalence (56%) of mutant P. jirovecii in adult patients. A prospective clinical 
study found that 61% of PCP patients were infected with mutant P. jirovecii. The 
overall in-hospital mortality was 21%. Significantly more patients died in hospital 
of mutant P. jirovecii than those infected with wild-type strains (P = 0.04). 
Mortality at three months among the discharged patients was associated with the 
wild-type genotype. However, cause of death was unknown. There were no 
significant associations in patients infected with P. jirovecii containing single 
DHPS mutations versus those infected with the M3 genotype. There was an 
insignificant trend for patients infected with M3 strains to have lower median 
CD4
+
 cell counts versus patients harbouring single mutant strains (P = 0.06). Few 
patients were exposed to sulfonamides and 58% of patients diagnosed with HIV 
on admission harboured mutant P. jirovecii. P. jirovecii strains, in a subset of 
clinical study patients, were characterized by ITS typing. Eleven bona fide ITS 
haplotypes, six ITS1 and nine ITS2 types, were found. Almost half of the patients 
harboured more than one P. jirovecii strain. Eg occurred at a high frequency of 
85%, and the presence of the local South African haplotype Eu was confirmed. 
Other ITS haplotypes detected were: Em, Ec, Eb, Bi, Gg, Ep, Fu4, Ne and Ai. 
Two novel ITS1 sequences SA1 and SA2 were detected. There were no obvious 
associations between ITS haplotype and a particular clinical characteristic or 
outcome. Eg haplotypes were more often associated with a wild-type DHPS 
genotype. Inter-human transmission of P. jirovecii carrying mutant DHPS 
genotypes could, at least in part, explain the high prevalence of DHPS mutations 
in adult HIV-positive South Africans. 
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C H A P T E R   O N E 
 
INTRODUCTION 
 
1.1 Literature Review 
 
1.1.1 History and Taxonomy 
Pneumocystis is an atypical fungus with a worldwide distribution, which 
opportunistically inhabits the lungs of humans and other mammals. The organism 
was first discovered over 100 years ago in Brazil by Carlos Chagas in the lungs of 
guinea pigs, and later in the lungs of a patient who died of trypanosomiasis.
(1-3)
 He 
was studying Trypanosoma cruzi in marmosets and experimentally infected 
guinea pigs, dogs and rabbits.
(4)
 Chagas incorrectly presumed that Pneumocystis 
was a developmental stage of that parasite. Antonio Carini had, in 1910, also 
discovered Pneumocystis in the lungs of Brazilian rats co-infected with 
Trypanosoma lewisi. He sent tissue samples to the Pasteur Institute in Paris, 
where the Delanöes, a husband and wife research team, were also studying rats.
(5)
 
The Delanöes observed similar cysts in the lungs of sewer rats and in 1912 they 
realized that Pneumocystis was a unique organism unrelated to trypanosomes. 
They proposed the name Pneumocystis carinii in honour of Antonio Carini, and 
because of the organism’s tropism for the lungs and cyst-like shape.(5-7) 
 
The next mention of Pneumocystis occurs 30 years later after the Second World 
War, when premature and malnourished infants in orphanages in Europe were 
dying of an interstitial pneumonia. It was discovered that Pneumocystis was the 
cause of these epidemics.
(8-10)
 The first case outside of Europe was described in an 
English infant who died 12 weeks after birth. Her alveoli “were filled with a 
peculiar foamy or honeycombed material”.(11) After the 1950’s Pneumocystis was 
associated with pneumonia in children with leukaemia, who were receiving 
immunosuppressive drugs.
(3)
 Thirty years ago in 1981, the Centers for Disease 
Control in the USA reported the unusual diagnosis of Pneumocystis pneumonia 
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(PCP) in five young men from Los Angeles.
(12)
 Pneumocystis suddenly became a 
major opportunistic infection in immunocompromised patients with the beginning 
of the acquired immunodeficiency syndrome (AIDS) epidemic. PCP in non-HIV 
immunosuppressed patients is becoming increasingly important as these patient 
numbers rise. This group of patients includes those with haematological and solid 
organ malignancies, allogeneic bone marrow and solid organ transplant recipients, 
and patients with autoimmune inflammatory disorders such as Wegener’s 
granulomatosis.
(13)
 
 
The name P. carinii was used for any Pneumocystis until it was discovered that 
Pneumocystis species were highly host-specific. As early as 1976, Frenkel et al 
(14)
 suggested that rat and human Pneumocystis should be treated as separate 
species, based on host specificity and phenotypic differences. It was only in the 
late eighties that Pneumocystis was found to be related to fungi, based on 
similarities in the nuclear small rRNA subunit.
(15-16)
 DNA analysis also showed 
the extensive diversity of the Pneumocystis genus and a rather lengthy name was 
adopted for the human form: P. carinii formae specialis hominis (P. carinii f. sp. 
hominis). In 1999, Frenkel again proposed the name P. jirovecii for the species 
that infects humans, and P. carinii is now only used to describe the species that 
occurs in rats.
(17-18)
 In 2006, Redhead et al 
(4)
 reviewed the classification and 
nomenclature of Pneumocystis and proposed guidelines for the publication of new 
species according to the International Code of Botanical Nomenclature (ICBN). 
 
Pneumocystis was initially classified as a protozoan parasite on the basis of early 
morphological observations, and the organism’s response to anti-protozoal drugs 
as opposed to antifungal drugs.
(18)
 Stages in its life cycle were described as cysts 
and trophozoites and these names are still in use today. However, Pneumocystis 
was found to have staining properties consistent with fungi. A component of the 
organism’s wall is β-1,3-glucan, which is a major component of fungal cell walls. 
Certain fungal genes were found in Pneumocystis, such as the gene for translation 
elongation factor 3 (EF-3), which is unique to fungal protein synthesis.
(19)
 The 
enzymes thymidylate synthase (TS) and dihydrofolate reductase exist as two 
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distinct enzymes in Pneumocystis, unlike protozoa where their activities are 
included in a single bifunctional protein.
(20-21)
 Pneumocystis was found to be 
related to the ascomycetous fungi with Schizosaccharomyces pombe as its closest 
relative species.
(22)
 The current classification of Pneumocystis according to the 
ICBN is as follows:
(4,23-24)
 
Eukaryota 
Kingdom: Fungi 
Phylum: Ascomycota 
Subphylum: Taphrinomycotina 
Class: Pneumocystidomycetes 
Order: Pneumocystidales 
Family: Pneumocystidaceae 
Genus: Pneumocystis 
Species: P. jirovecii, P. carinii, P. murina, P. wakefieldiae 
 
1.1.2 Prevalence and Incidence of Pneumocystis Pneumonia 
P. jirovecii causes a life-threatening pneumonia in immunocompromised patients 
and infants less than six months of age. Persons who are immunologically normal 
usually do not develop clinically important disease.
(3)
 Acute primary infection 
usually presents in patients previously unaware of their HIV status.
(25)
 
Corticosteroid use, neutropenia and immune suppression related to organ 
transplantation are major non-AIDS predisposing factors for P. jirovecii 
infection.
(26)
 The mortality rate of PCP in HIV-infected adult patients has 
remained unchanged over the past 20 years, at an average of 12%.
(27-28)
 Morrow et 
al, 2010 reported a high in-hospital case fatality rate of 39% for infants with PCP 
in South Africa.
(29)
 
 
The incidence of PCP, which increased dramatically with the advent of the 
HIV/AIDS pandemic, has decreased in the industrialised world owing to the 
widespread use of sulfa drug prophylaxis and the introduction of highly active 
antiretroviral therapy (HAART).
(3)
 Even with ready access to HAART, 
P. jirovecii remains the leading cause of serious opportunistic infection in HIV-
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infected patients, particularly those unaware of their HIV status.
(27)
 PCP is an 
important cause of morbidity and mortality in immunocompromised non-HIV-
infected patients in whom its incidence is increasing.
(30-31)
 
 
Studies from African countries report variable prevalences of PCP in adult 
HIV/AIDS patients and generally higher rates in children (Table 1.1).
(29,32-47)
 The 
mean prevalence of PCP in African children calculated from studies in Table 1.1 
is 27% (range 10%-49%), and in adults it is 18% (range 4%-43%). Some of these 
studies were based on autopsy findings, whilst others were hospital-based with 
various selection criteria and specimen types. Most of the prevalence studies from 
Africa used only one diagnostic method to detect P. jirovecii, and the different 
diagnostic methods have variable sensitivities for the detection of P. jirovecii. 
Post-mortem lung biopsies of HIV-positive Zimbabwean infants, who died of 
pneumonia, were tested for P. jirovecii using a combination of three different 
methods. PCR detected most cases, followed closely by cytological staining and 
the least number of cases were detected by histology.
(46)
 In South Africa, where a 
limited number of laboratories offer testing for P. jirovecii, the vast majority of 
PCP cases are diagnosed clinically and radiologically. These factors make it 
difficult to establish prevalence rates for this disease. In South African children 
infected with HIV, PCP is a major cause of hospitalization and mortality, despite 
the availability of HAART.
(29,41)
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Table 1.1 Prevalence of PCP in Sub-Saharan Africa 
Country Reference Adults/children,  
HIV status 
Study type Total 
patients 
Percentage 
prevalence 
Concurrent infections with 
PCP 
PCP TB 
Botswana Ansari  
2002 
(32)
 
 Adults, HIV-positive Autopsy, died of pulmonary 
disease, suspected PCP 
104 11 40 NS 
Botswana Ansari  
2003 
(33)
 
 Children ≤13y, HIV-
positive 
Autopsy, death all causes 35 29 11 NS 
Ethiopia Aderaye 
2007 
(34)
 
Adults, HIV-positive  Hospital, , smear negative TB 
patients 
131 30 24 13% (17/131) of all 
patients had coinfections 
Cote 
d’Ivoire 
Lucas  
1996 
(35)
 
Children <15m, HIV-
positive  
Autopsy, death all causes 36 31 0 NS 
Kenya Chakaya 
2003 
(36)
  
Adults, HIV-positive Hospital, smear negative TB 
patients 
51 37 NS 8/19 (42%) PCP patients 
coinfected with another 
organism 
Malawi Hargreaves 
2001 
(37)
 
Adults, 88% were 
HIV-positive 
Hospital, smear negative TB 
patients 
186 9 NS 2/17 (12%) PCP patients 
coinfected with PTB 
South 
Africa 
Garcia-
Jardon 2010 
(38)
 
Adults & children 
(14% <18 years), 
HIV-positive 
Autopsy, included all patients 
who died in hospital 
86 9 38 NS 
South 
Africa 
Morrow 
2010 
(29)
 
Children <5m, 61% 
were HIV-positive 
Hospital,  patients with acute 
hypoxic pneumonia 
202 21 3 30/43 (70%) PCP patients 
coinfected with another 
organism, mainly CMV 
South 
Africa 
Murray 
2007 
(39)
 
Adult gold miners, 
HIV-positive,  
Autopsy, death all causes 66 14 21 NS 
South 
Africa 
Wong  
2006 
(40)
 
Adult miners, HIV-
positive and negative 
Lung autopsy, death all causes 8421 4 NS 107/328 (33%) PCP 
patients coinfected with 
another microorganism 
 
 
     
 18 
Table 1.1 Continued  
Country Reference Adults/children,  
HIV status 
Study type Total 
patients 
Percentage 
prevalence 
Concurrent infections with 
PCP 
South 
Africa 
Ruffini 
2002 
(41)
 
Children <2y, HIV-
positive  
Hospital, severe pneumonia 105 49 3 9/51 (18%) PCP patients 
coinfected with a 
respiratory viral infection 
or bacteraemia. 
South 
Africa 
Zar  
2000 
(42)
 
Children, HIV-
positive  
Hospital, pneumonia 151 10 NS NS 
South 
Africa 
Mahomed 
1999 
(43)
 
Adults, HIV-positive 
Adults, renal 
transplant recipients 
Hospital, smear negative TB 
patients with a lower respiratory 
tract infection 
67 
 
36 
43 
 
31 
13 
 
17 
NS 
Uganda Worodria 
2003 
(44)
 
Adults, HIV-positive  Hospital, smear negative TB 
patients 
83 39 24 5/32 (16%) PCP patients 
coinfected with PTB 
Zambia Chintu  
2002 
(45)
 
Children <16y, 68% 
were HIV-positive 
Chest autopsy, died of respiratory 
disease 
264 22 20 43/58 (74%) PCP patients 
coinfected with another 
lung pathogen 
Zimbabwe Nathoo 
2001 
(46)
 
Children <6m, HIV-
positive  
Post mortem lung biopsy, died of 
pneumonia 
24 67 0 5/16 (31%) PCP patients 
coinfected with a bacterial 
pathogen 
Zimbabwe Malin  
1995 
(47)
 
Adults, HIV-positive  Hospital, smear negative TB 
patients, diffuse pneumonia 
unresponsive to penicillin 
64 33 39 6/21 (29%) PCP patients 
coinfected with PTB 
PCP Pneumocystis pneumonia, TB tuberculosis, PTB pulmonary tuberculosis, CMV cytomegalovirus, NS not stated, 
§episodes/events 
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1.1.3 Life Cycle and Transmission 
The putative life cycle of Pneumocystis is based on ultrastructural observations, as 
no reliable long-term culture system has been developed (Figure 1.1). The route of 
human infection is assumed to be airborne via spores, but this infectious stage of 
the life cycle has yet to be isolated.
(48)
 Pneumocystis has a tropism for the lungs 
and attaches to alveolar epithelial cells. Haploid trophic forms replicate by binary 
fission during the asexual phase. The fungus proliferates and fills the alveolar 
spaces, causing lung injury and hypoxia. Matsumoto et al, 
(49)
 found the presence 
of synaptonemal complexes, indicating meiotic division, followed by nuclear 
divisions in Pneumocystis infecting rat alveoli. This discovery of a Pneumocystis 
sexual cycle occurring in animals is most unusual for fungi.
(50)
 During the sexual 
phase two presumptive mating types conjugate, undergo karyogamy, and produce 
a diploid zygote. The zygote undergoes meiosis and then mitosis to produce eight 
nuclei. The nuclei are packaged into spores by invagination of the ascus cell 
membranes. Excystment occurs via protunicate release by unknown mechanisms, 
and the spores become the vegetative forms that undergo asexual or sexual 
replication.
(48)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Putative life cycle of Pneumocystis.
(48)
  
Permission to use this diagram was obtained from the American Society for 
Microbiology, license number: 2695350073704, 24 June 2011. 
 20 
 
P. jirovecii is not a zoonotic disease, as Pneumocystis species are highly host-
specific. The most likely route of transmission of P. jirovecii organisms is person-
to-person via the airborne route. Evidence for this is provided by the 
demonstration of airborne transmission in rodent models, the detection of 
P. jirovecii DNA in exhaled air samples from PCP patients, and cases of 
nosocomial clustering.
(51-53)
 An outbreak of PCP was described in 16 renal 
transplant patients attending an outpatient department at a medical centre in The 
Netherlands 
(53)
 The identical ITS haplotype was found in 75% of patients, and 
researchers concluded that their results were compatible with inter-human 
transmission or a common environmental source of infection. 
 
Two-thirds of immunocompetent children have been exposed to Pneumocystis 
organisms, demonstrated by the presence of serum antibodies, by the age of four 
years.
(54-55)
 This indicates that the fungus is ubiquitous, and raises the question of 
how these infants become exposed at such an early age. It is likely that the spores 
are the infectious stage in the life cycle with their resistant wall, allowing the 
fungus to potentially survive in the environment. Cushion et al 
(56)
 found strong 
evidence for the spore as the agent of transmission when studying P. muris in 
mice. On the other hand, immunocompetent adults have been proposed as 
reservoir hosts for P. jirovecii, as carriage or colonization in the respiratory tract 
of healthy individuals has been demonstrated.
(57)
 Asymptomatic carriage of 
P. jirovecii in healthcare workers in close contact with PCP patients has been 
described.
(58)
 Transplacental transmission of P. jirovecii has been demonstrated in 
rabbits, and vertical transmission was detected in aborted foetuses of 
immunocompetent women by molecular techniques.
(59-60)
 However, placental 
transmission of P. carinii in rats was not demonstrated.
(61)
 A case of potential 
transmission from immunocompetent grandparents to an infant was reported from 
Spain.
(62)
 Both grandparents were colonized with P. jirovecii, and the 
grandmother had a history of rheumatoid arthritis, and the grandfather suffered 
from chronic bronchitis. Patients with chronic pulmonary diseases, such as 
chronic obstructive pulmonary disease (COPD), have been shown to be colonized 
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with P. jirovecii and are suggested to be reservoirs of this fungus.
(63-64)
 HIV-
infected patients with PCP are a likely source of infection in localities with high 
prevalence rates. A combination of all of the above acting as potential reservoirs 
of infection could account for the ubiquitous nature of this fungus. 
 
There has been much debate around reactivation of a latent P. jirovecii infection, 
perhaps acquired as an infant, versus reinfection. Evidence for de novo acquisition 
of P. jirovecii with mutant DHPS genotypes has been provided by studies 
including patients who had never received sulfa drug prophylaxis for PCP.
(65-66)
 In 
one of these studies, more than half of the patients newly diagnosed with HIV 
infection had mutant P. jirovecii.
(66)
 This suggests recent infection with strains 
from other patients who were exposed to sulfa medications. Genotyping studies 
have also supported recent transmission with clusters of PCP cases having a single 
predominant P. jirovecii genotype.
(53)
 Patients with recurrent infections have 
shown genotype switching in support of this hypothesis.
(67)
 
 
1.1.4 Host Defence 
Pneumocystis organisms attach to alveolar epithelial cells and the alveolar 
macrophages are the first line of defence to prevent infection. To counter this, 
Pneumocystis organisms reduce the ability of alveolar macrophages to 
phagocytose, as well as decrease their numbers by inducing apoptosis.
(48)
 Much of 
the lung damage with a Pneumocystis infection is due to inflammation. The 
immune response to Pneumocystis is complex and involves both the humoral and 
cellular immune systems.
(68-69)
 CD4
+
 T lymphocytes are essential to clear 
P. jirovecii infection, and most infections occur in immunocompromised patients 
with lower than 200 cells/mm
3
. CD8
+
 T lymphocytes work together with the 
CD4
+
 cells, but play a less significant role in host defence against Pneumocystis. 
CD8
+
 T lymphocytes have been shown to decrease the severity of PCP.
(68)
 B 
lymphocytes act as effector cells against Pneumocystis infection, and are 
important in the generation of CD4
+
 memory T cells.
(68-69)
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1.1.5 Diagnosis and Clinical Manifestations 
 
1.1.5.1 Clinical Manifestations 
PCP patients usually present with dyspnoea (shortness of breath), a non-
productive cough and hypoxaemia. PCP is an AIDS-defining infection and HIV-
infected patients present subacutely with progressive dyspnoea, low grade or no 
fever, and malaise. Non-HIV immunosuppressed patients, such as those with 
malignancies or transplant recipients, present with a more acute illness. These 
patients have substantial shortness of breath causing severe respiratory distress 
that frequently requires urgent mechanical ventilation. The clinical presentation in 
PCP patients can vary and may mimic other infections or disease processes.
(3,10,13)
 
 
Typical chest radiography shows bilateral, diffuse interstitial infiltrates involving 
the perihilar regions, with sparing of the apices. However, all types of atypical 
chest radiographs have been linked with PCP. A high resolution computed 
tomography scan is more sensitive than chest x-ray and shows the characteristic 
bilateral groundglass opacities of PCP.
(3,10,13)
 
 
1.1.5.2 Laboratory Diagnosis 
The laboratory diagnosis of P. jirovecii can be made within 2 hours on an induced 
sputum specimen, stained with a fluorescent monoclonal antibody. Treatment 
based on a confirmed diagnosis, as opposed to empirical therapy, ensures that the 
patient receives the appropriate medication and potentially toxic medications are 
avoided. Bronchoalveolar lavage fluid (BAL) is considered the best specimen 
type for P. jirovecii diagnosis, apart from a lung biopsy. 
 
Immunofluorescence (IF) microscopy is commonly used for the laboratory 
diagnosis of P. jirovecii. A UV microscope equipped with the correct wavelength 
filter is required, as well as an experienced microscopist. Commercial kits are 
available for either direct or indirect fluorescent staining with monoclonal 
antibodies. All kits are able to stain the so-called “cyst” forms, but not all kits can 
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reliably stain the smaller trophic forms. The analytical sensitivity of IF 
microscopy is high and the specificity is good.
(69)
 
 
Molecular techniques, such as real-time PCR, are becoming more popular and are 
often used in conjunction with IF microscopy. Several in-house real-time PCR 
methods targeting various genes have been developed to replace nested PCR and 
gel electrophoresis.
(69)
 One of the most common gene targets is that coding for the 
mitochondrial large subunit (mtLSU). The highly sensitive nature of PCR creates 
a challenge when interpreting PCR-positive results with low copy numbers and 
negative IF microscopy results. Distinguishing between colonization and active 
clinical disease is not easy. 
 
Cytological staining techniques to diagnose P. jirovecii are still used in some 
institutions, as well as in resource-poor settings. Grocott’s methenamine silver, 
toluidine blue O and calcofluor white stains can be used to stain the “cyst-like” 
forms (Figure 1.2).
(13)
 Giemsa is a non-specific stain that colours all nuclear 
material red and cytoplasm blue. Trophic forms and “intracystic bodies” are 
stained with Giemsa, however the cell wall does not take up stain leaving a 
characteristic halo around the “cyst”. Giemsa-stained smears are time-consuming 
and difficult to read, especially sputum smears that may contain many cells and 
other microorganisms. The sensitivity and specificity of the different cytological 
stains varies depending on the specimen type and experience of the microscopist. 
Cytological stains are generally less sensitive than IF microscopy.
(69)
 
 
Tissue sections of lung biopsy specimens have long been stained with the non-
specific histological stain of haematoxylin and eosin (H&E). The presence of 
foamy pink exudates filling the alveolar spaces is typical of P. jirovecii.
(3)
 The 
classical Grocott’s methenamine silver stain, which was widely used in the past, is 
mainly reserved for histological specimens. 
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Figure 1.2 P. jirovecii stained with toluidine blue O (1000x magnification) 
 
The idea of a quick, cheap, non-invasive serological test for P. jirovecii is 
enticing. Unfortunately, the main disadvantage of the current techniques is the 
lack of a high degree of specificity. Tests that measure serum lactate 
dehydrogenase (LDH) and S-adenosylmethionine (SAM) have not yet 
demonstrated performance characteristics to suggest that they can be useful for 
the diagnosis of P. jirovecii.
(70)
 Elevated serum levels of LDH have been 
associated with PCP, but are not specific. SAM is essential for methylation 
reactions and polyamine biosynthesis.
(71)
 Pneumocystis was thought to lack the 
enzyme SAM synthase, and needed to acquire this metabolic intermediate from its 
human host. Low or undetectable levels of SAM have been reported in PCP 
patients, with a rise in concentration as the patient recovers.
(71)
 However, de Boer 
et al 
(72)
 studied 31 patients, 21 of whom were PCP-positive, and found that SAM 
levels did not discriminate between patients with and without PCP.  
 
β-glucan, (1→3)-β-D-glucan, is a polysaccharide cell wall component in many 
fungi, including Pneumocystis.
(73)
 This polysaccharide triggers an innate immune 
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response and can be measured in blood and BAL specimens.
(70)
 In the largest 
study to date, Sax et al, 2011, measured plasma β-glucan levels in a group of 282 
HIV-positive patients.
(73)
 They found that PCP patients had higher levels of β-
glucan (median 408 pg/ml) compared to those without PCP (median 37 pg/ml), 
and the test had an analytical sensitivity of 92%. However the specificity was only 
65%, which is lower than that for stains of induced sputum. Other invasive fungal 
infections caused elevated levels of β-glucan. The levels of β-glucan did not 
correlate with disease severity or response to treatment. The test was cheaper than 
IF microscopy in their setting. 
 
1.1.6 Management of PCP 
Untreated PCP in AIDS patients is almost invariably fatal. Management of the 
disease in patients with AIDS falls into two categories: therapy for acute primary 
infection and prophylaxis for those whose HIV infection status is known. 
Antiretroviral drugs are an integral part of therapy for acute primary PCP.
(25)
 
Sulfonamides, usually combined with trimethoprim as in trimethoprim-
sulfamethoxazole (TMP-SMX, also known as co-trimoxazole), and dapsone are 
used for the treatment and prophylaxis of PCP. TMP-SMX is the drug of choice 
for both the treatment and prophylaxis of mild, moderate and severe PCP. In HIV 
patients the recommended treatment is trimethoprim 15-20 mg/kg/day plus 
sulfamethoxazole 75-100 mg/kg/day for 21 days. In non-HIV patients, the 
duration of treatment can be shortened to 14 days, with decreased risk of 
relapse.
(74)
 Clinical improvement should occur within 4-7 days.
(25)
 TMP-SMX 
may cause significant toxicity in up to 40% of patients, but a gradual introduction 
of TMP-SMX may improve tolerance to the drug.
(75)
 Adjunctive corticosteroids 
are recommended for patients with moderate to severe PCP.
(74)
 
 
There are few alternatives for those who cannot tolerate TMP-SMX. Regimens 
include intravenous pentamidine, clindamycin plus primaquine, trimethoprim plus 
dapsone and atovaquone suspension.
(74)
 Intravenous pentamidine isethionate is an 
alternative for patients with severe PCP who are intolerant or unresponsive to 
TMP-SMX.  Aerosolized pentamidine has also been used for the treatment of 
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active disease, but is associated with unacceptably high relapse rates, as well as 
the promotion of atypical pulmonary and/or extrapulmonary P. jirovecii infection, 
and is not considered adequate therapy for PCP.
(76-77)
 
 
PCP prophylaxis has decreased the incidence of the disease and increased the 
median survival of AIDS patients.  It also appears to delay the first AIDS-defining 
illness by six to 12 months and patients have lower CD4 counts at the time of 
diagnosis.  Prophylaxis is indicated for any HIV-infected adult or adolescent, 
including pregnant women, with a CD4 count of less than 200 cells/mm
3
.
(77)
 
TMP-SMX is the recommended first-line treatment for prophylaxis against 
PCP.
(74)
 Failure of prophylaxis may be due to resistance to the agent of choice, or 
may reflect factors such as poor compliance or unfavourable pharmacokinetics. It 
has been suggested that when PCP develops in patients receiving prophylaxis, 
therapy should be instituted with a different agent, at full dose, rather than the one 
used for prophylaxis.
(25)
 
 
1.1.7 DHPS Mutations and Drug Resistance 
Sulfonamides inhibit the enzyme dihydropteroate synthase (DHPS) and 
trimethoprim inhibits dihydrofolate reductase (DHFR), which are essential 
components of the folate synthesis pathway.
(78)
 Pneumocystis organisms require 
the synthesis of folates, and the role that these two enzymes play in this process of 
folic acid biosynthesis is illustrated in Figure 1.3. DHPS catalyses the 
condensation of para-aminobenzoic acid (PABA) and pteridine to form 
dihydropteroic acid. Further steps in this pathway lead to folic acid synthesis and 
eventually DNA synthesis.  Sulfa drugs are chemical analogues of PABA and 
bind to DHPS, thus competitively inhibiting the enzyme and folate synthesis 
(Figure 1.4). DHPS gene mutations are thought to cause structural changes in the 
enzyme’s substrate binding site, which interfere with sulfonamide binding and 
decrease the affinity to these drugs. Point mutations in the DHPS-encoding gene 
of other microorganisms such as Plasmodium falciparum, Staphylococcus aureus, 
Mycobacterium leprae and Escherichia coli have been shown to confer resistance 
to sulfonamides.
(79-83)
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In P. jirovecii, two nonsynonymous point mutations in the fas gene encoding the 
DHPS enzyme are associated with prior exposure to sulfa drugs.
(66-67,84-87)
 There 
are concerns about the possible emergence of sulfonamide resistance in this 
organism. These single nucleotide mutations, at positions 165 and 171, cause 
amino acid substitutions at positions 55 (threonine to alanine, so called mutation 
M1) and 57 (proline to serine, mutation M2) in the DHPS protein, respectively. 
The presence of both mutations is denoted as mutation M3, and the wild-type 
sequence is commonly accepted as the one with no substitutions (DHPS sequence 
in GenBank AF139132). As P. jirovecii cannot yet be cultured, conventional in 
vitro susceptibility tests cannot be utilized to ascertain drug resistance; therefore, 
studies of drug resistance in this organism rely on the use of genetic markers and 
suitable models. Functional complementation of either DHPS-disrupted E. coli 
with mutant P. jirovecii fas gene, or FOL1-disrupted Saccharomyces cerevisiae 
with the fol1 gene mutated at nucleotide positions analogous to 165 and 171 in 
fas, result in loss of susceptibility to sulfamethoxazole and other sulfa-containing 
drugs.
(88-89)
 
 
The clinical significance of DHPS mutations in P. jirovecii is not fully understood 
and the few studies that have investigated the clinical effects of these mutations 
showed conflicting results.
(65,67,84,86-87,90-94)
 These studies used different definitions 
for patient outcome, as well as different time points for their assessments. Some 
studies from the developed world have used pooled retrospective data from 
several countries, as a limited number of clinical studies had adequate sample 
sizes for the mutant DHPS genotype category. Table 1.2 summarizes results from 
ten studies that had at least 14 patients in the mutant DHPS category.  
 
An early study from 1999 by Helweg-Larsen et al,
(67)
 found a significantly lower 
three-month survival in patients infected with mutant P. jirovecii compared to 
patients infected with wild-type organisms. In contrast, two other studies 
(84,93)
 
found no significant association between patient survival and DHPS genotype at 
four and six weeks respectively. Huang et al 
(90)
 found an insignificant trend for 
 28 
patients infected with mutant P. jirovecii DHPS to have an increased mortality, 
whilst Nahimana et al 
(86)
 had similar in-hospital rates of death for patients with or 
without mutant P. jirovecii. Crothers et al 
(87)
 found that mortality was not 
associated with the presence of P. jirovecii containing DHPS mutations. Whether 
the presence of DHPS gene mutations confers clinical resistance to sulfonamides 
remains unclear and requires further study. 
 
1.1.8 Prevalence of P. jirovecii DHPS Mutations 
The prevalence of P. jirovecii DHPS mutations reported from countries in the 
developed world ranges widely, from 0% to 81% (Figure 1.5).
(65,67,84-87,90-99)
 
Studies from the USA generally report the highest prevalences of P. jirovecii 
DHPS mutations, with an average of 67% calculated from Figure 1.5. European 
countries by contrast, have much lower prevalences with an average of 17%. The 
few studies performed in developing countries all report low prevalences of 
P. jirovecii containing DHPS mutations (Table 1.3). A study from 2003, based on 
a small sample size of 14 patients, reported a prevalence of P. jirovecii DHPS 
mutations in 7% of Zimbabwean HIV-infected adults with PCP. 
(100)
 In South 
Africa, a handful of studies that screened specimens from limited numbers of 
adults and children have reported low mutation prevalences of up to 13%.
(101-103)
 
The apparent low prevalence of DHPS mutations in P. jirovecii from developing 
countries has been assumed to be the result of limited availability of sulfa drug 
prophylaxis against PCP. 
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Figure 1.3 Folate synthesis pathway and the roles of the DHPS and DHFR 
enzymes (adapted from Huang et al 
(104)
).  
DHPS dihydropteroate synthase, DHFR dihydrofolate reductase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Inhibition of the folate synthesis pathway by sulfonamides. 
DHPS dihydropteroate synthase 
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Table 1.2 Results from studies (≥14 patients in the mutant category) investigating the clinical significance of P. jirovecii DHPS mutations 
No. of patients, 
country, patient type 
DHPS mutations 
(%), prevalent 
genotype 
Sulfa prophylaxis 
associated with 
DHPS mutations 
Clinical significance of DHPS mutations Reference 
372
a
, UK & USA, 
HIV+ 
268
a
 (72), 
not stated 
Yes City of residence associated with presence of DHPS 
mutations. Insignificant trend for patients with mutant 
strains to have increased mortality at 6 weeks. 
Huang 2006 
(90)
 
215
a
, USA,  
HIV+ adults,  
175
a
 (81),  
M3 (113/175) 
Yes Presence of DHPS mutations not associated with 
mortality at 60 days. Trend for patients with mutant 
strains to have worse outcomes vs WT. 
Crothers 2005 
(87)
 
194, France, HIV+/- 
adults & children 
64 (33), 
M2 (42/64) 
Yes Suboptimal prophylaxis - failure associated with 
mutant strains. 
Hauser 2010 
(91)
 
158, France,  
76% HIV+ adults  
57 (36), 
M2 (36/57) 
Yes Rates of death (in hospital) attributed to PCP similar in 
patients with or without mutant strains. 
Nahimana 
 2003 
(86)
 
154, Italy,  
HIV+ adults 
14 (9), 
M1 (6/14) 
No Correlation between DHPS mutants and greater 
severity of PCP and worse outcomes. 
Valerio 2007 
(92)
 
144, Denmark, 
HIV+ adults 
29 (20),  
M1 (18/29) 
Yes Significantly lower 3-month survival in patients with 
mutant DHPS strains. 
Helweg-Larsen  
1999 
(67)
 
136, USA, 
HIV+ adults 
97 (71),  
M3 (72/97) 
N/A No association between DHPS genotype & death at 6 
weeks. 
Navin 2001 
(93)
 
98, Spain 
HIV+ adults 
17 (17), 
M3 (8/17) 
Yes Similar in-hospital, 3-month & 6-month mortality rate 
regardless of DHPS genotype. 
Alvarez-Martinez 
2010 
(94)
 
97, USA 
HIV+ adults 
42 (43),  
M3 (41/42) 
Yes No significant difference in survival at 4 weeks. 
Patients with mutant strains had significantly increased 
risk for failure of sulfa/sulfone therapy vs WT.  
Kazanjian 
 2000 
(84)
 
92, France, 90% 
HIV+ 
16 (17), 
M3 (4/16) 
No No difference in outcome according to DHPS 
genotype.  
Latouche 2003 
(65)
 
a
 Episodes or specimens, HIV+ HIV-positive, HIV- HIV-negative, WT wild-type 
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Figure 1.5 Prevalence of DHPS mutations in P. jirovecii from studies conducted in developed countries 
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Table 1.3 Prevalence of P. jirovecii containing DHPS mutations from studies 
conducted in developing countries 
Country Year Sample size 
(n = patients) 
DHPS 
mutation 
prevalence (%) 
Reference 
South Africa  
 
2008 6 0 Govender  
2008 
(103)
 
South Africa  
 
2005 53
a
 1 (2) Robberts 
 2005 
(102)
 
South Africa  
 
2004 30 4 (13) Zar 2004 
(101)
 
Zimbabwe  
 
2003 14 1 (7) Miller  
2003 
(100)
 
Brazil  
 
2006 57 0 Wissmann 
2006 
(105)
 
China  
 
2009 10 0 Li 2009 
(106)
 
China  
 
2004 15 1 (7) Kazanjian 
2004 
(107)
 
India  
 
2010 24
b
 1 (4) Tyagi 2011 
(108)
 
India  
 
2008 5 0 Tyagi 2008 
(109)
 
a
 PCP episodes, not patients 
b 
non-HIV-infected patients 
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1.1.9 Strain Characterization Based on ITS Typing 
Conventional microbial typing methods for Pneumocystis are not possible, as the 
organism cannot be cultured for a lengthy period of time. Instead, genetic loci 
with nucleotide sequence variation have been used for strain characterization, and 
include the mitochondrial large-subunit rRNA (mt LSU rRNA), the major surface 
glycoprotein (MSG), beta-tubulin (β-TUB), thymidylate synthase (TS), 
cytochrome b (CYB), superoxide dismutase (SOD), thioredoxin reductase (Trr1), 
dihydrofolate reductase (DHFR), the dihydropteroate synthase (DHPS) region of 
the fas gene, and the internal transcribed spacer (ITS) regions in the nuclear 
ribosomal RNA gene complex. ITS and MSG sequences show marked diversity, 
but the other loci have been poor candidates for strain typing due to their low 
sequence diversity.  
 
Characterization of P. jirovecii strains in this research study was performed by 
analysis of sequence variation in the ITS regions in the nuclear rRNA gene 
complex. The ITS regions show great diversity among Pneumocystis strains and 
provide an informative epidemiological tool for the typing of these strains.
(110)
 
There are two ITS regions in the genome of Pneumocystis. The ITS1 region is 
located between the genes encoding the 18S rRNA and the 5.8S rRNA, and the 
ITS2 region lies between the 5.8S rRNA and the 26S rRNA genes (Figure 1.6). 
The ITS regions are processed by splicing events during the maturation of the 
rRNA molecules. Most fungi have multiple copies of rRNA genes and the ITS 
regions are usually conserved within species, providing a species-specific 
signature. However, the nuclear ribosomal genes of Pneumocystis exist as a single 
copy, and there is considerable intra-specific sequence variation.
(111)
 
 
18S rRNA ITS1 5.8S rRNA ITS2 26S rRNA 
 
Figure 1.6 Schematic diagram of the nuclear ribosomal gene complex of 
Pneumocystis showing the positions of the non-coding ITS1 and ITS2 
regions (based on Lu et al 
(110)
) 
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ITS typing methods have been devised by Lee et al 
(112)
 and Tsolaki et al.
(113)
 
Different naming systems were devised for the various ITS types, making the 
comparison and interpretation of their results complicated and sometimes 
impossible if not enough information is provided in the publications. For this 
study Lee’s system for the naming of ITS haplotypes was used. The uppercase 
letter represented the ITS1 type and the lowercase letter represented the ITS2 
type.
(112)
 At least 100 ITS haplotypes have been described to date, and more than 
30 ITS1 types and 40 ITS2 types. The diversity of ITS haplotypes is lower in 
reality, as some of the haplotypes have been proven to be artifacts generated by 
the PCR method. Beser et al, 2007 showed that chimeric ITS sequences were 
produced at high rates during PCR amplification of specimens that were co-
infected with more than one ITS haplotype.
(114)
 Under standard PCR conditions 
using Taq polymerase, up to 37% of the amplified sequences were hybrid DNA 
artifacts. By modifying the PCR amplification conditions, the formation if ITS 
chimeras could be largely abolished and the erroneous establishment of artifactual 
haplotypes was avoided. 
 
Co-infections with more than one ITS haplotype are common. According to Lee 
et al 
(112)
, a sequence found in two or more specimens is considered a distinct 
haplotype (a combination of ITS1 and ITS2 sequences). Beser et al 
(114)
 suggested 
that a single infection is the only true basis for the definition of a bona fide 
P. jirovecii ITS haplotype. 
 
The most common ITS haplotype is Eg, which occurs worldwide. Ne, Ai and Eb 
haplotypes have been reported from many countries.
(112,115-117)
 The ITS haplotype 
Ne was associated with an outbreak of PCP in renal transplant patients attending 
an outpatient department at a medical centre in The Netherlands.
(53)
 The same Ne 
ITS haplotype was found in 75% of patients. A single study from South Africa 
has investigated the ITS haplotypes in P. jirovecii organisms from 19 patients.
(118)
 
The global haplotype Eg was most prevalent, and was found in 74% of patients. 
The second most common haplotype was Gg occuring in 21% of patients. A new 
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ITS2 type u was described in three patients and was associated with an E in the 
ITS1. It remains to be seen if Eu is a local P. jirovecii ITS haplotype. 
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1.2 Objectives 
 
The purpose of this research was to investigate the prevalence of P. jirovecii 
strains containing dihydropteroate synthase (DHPS) mutations in South Africa, 
and to ascertain their clinical significance in HIV-positive patients with 
Pneumocystis pneumonia. The molecular epidemiology of P. jirovecii was 
explored by characterizing the strains circulating in HIV-infected patients. 
 
The research included the following objectives: 
 
1.2.1 To investigate the presence of DHPS polymorphisms in P. jirovecii strains 
in South Africa (Chapter Three). 
 
1.2.2 To determine the prevalence of DHPS polymorphisms in the general  
P. jirovecii population in South Africa (Chapter Four). 
 
1.2.3 To ascertain the clinical significance of P. jirovecii DHPS polymorphisms in 
HIV-infected patients with PCP (Chapter Five). 
 
1.2.4 To characterize the P. jirovecii strains circulating in HIV-infected patients 
and explore potential correlations with DHPS genotype and patient outcome 
(Chapter Six). 
 
It was hypothesized that the prevalence of DHPS polymorphisms in P. jirovecii 
strains in South Africa would be low, i.e. less than 15%. Two smaller studies from 
South Africa and a few studies performed in other developing countries, all 
reported low prevalences of P. jirovecii containing DHPS mutations (Table 1.3). 
It was important to perform a large prevalence study sampling patients from 
different parts of South Africa, as the overall prevalence of DHPS polymorphisms 
in the P. jirovecii population was unknown. 
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It was hypothesized that patients infected with P. jirovecii containing mutant 
DHPS genotypes would have poor clinical responses to treatment with sulfa-
containing drugs. It was important to perform a clinical study, as the clinical 
significance of DHPS mutations in P. jirovecii is not fully understood and the few 
studies that have investigated the clinical effects of these mutations showed 
conflicting results (Table 1.2). If the presence of DHPS gene mutations confers 
clinical resistance to sulphonamides, then this will have severe implications for 
the treatment of this disease.  
  
It was hypothesized that the diversity of P. jirovecii ITS haplotypes circulating in 
South Africa would be lower than previously reported 
(118)
 and that the most 
common ITS haplotype would be the global Eg haplotype. In addition it was 
hoped to confirm the presence of the Eu haplotype in the South African 
P. jirovecii population.  
 
1.3 Candidate’s role in the studies 
The candidate performed all molecular analyses for the prevalence study (Chapter 
Four) and the ITS characterization study (Chapter Six) at the Swedish Institute for 
Infectious Disease Control (SMI) in Sweden. The molecular analyses for the 
clinical study (Chapter Five) were performed both at SMI and at the National 
Institute for Communicable Diseases (NICD) in South Africa. The candidate had 
help from a Masters student in South Africa to perform some of the analyses for 
the clinical study, as well as the cloning of mixed DHPS genotypes. The candidate 
performed all data analysis and drafted the publications.
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C H A P T E R   T W O 
 
METHODS AND MATERIALS 
 
2.1 Laboratory Setting 
The Parasitology Reference Unit of the National Institute for Communicable 
Diseases (NICD), in Johannesburg, South Africa, is the largest recipient of 
referrals for the microbiological confirmation of P. jirovecii infection in the 
country, receiving about 1000 specimens annually. Specimens were processed at 
the NICD, as well as at the Swedish Institute for Infectious Disease Control 
(SMI), in Solna, Sweden.  
 
2.2 Hospital Setting 
The clinical study in Chapter Five was conducted at Chris Hani Baragwanath 
Hospital, in Soweto, South Africa. This is one of the largest hospitals in the world 
with 2 700 beds (maximum 3 200) in current use and serves an estimated 
population of four million people. 
 
2.3 Specimens and Patient Information 
 
2.3.1 Pilot Study (Chapter Three) 
A subset of 79 respiratory specimens from 65 patients were non-randomly chosen 
for the screening of P. jirovecii DHPS polymorphisms. The specimens were 
received at the National Institute for Communicable Diseases (NICD) in 
Johannesburg for the routine diagnosis of P. jirovecii from April 2003 through 
September 2004. The majority of specimens were sputa, and two specimens were 
bronchial washings. All of the specimens were positive for P. jirovecii by 
immunofluorescence (IF) microscopy. The patients were hospitalized in 12 
hospitals in four provinces of South Africa: Gauteng (46 patients), North West (11 
patients), Eastern Cape (5 patients) and Mpumalanga (3 patients). The mean age 
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of patients was 34 years (range 17-59 years) and 56% were female. Data 
concerning the HIV status of patients were not available. 
 
2.3.2 DHPS Prevalence Study (Chapter Four) 
Respiratory specimens (n = 932) from patients with suspected PCP (n = 712) were 
referred to the NICD from 38 public hospitals and clinics in six provinces of 
South Africa from January 2006 through February 2007. Data regarding patient 
age, gender and hospital location were extracted retrospectively from a laboratory 
information system. The mean age of patients was 34 years (SD±13), with a range 
of one month to 86 years (age was unknown in 81 patients). The female to male 
ratio was 1.6:1 (gender was unknown in 18 patients). Most patients (n = 491/712, 
69%) were from Gauteng Province, and the rest were from the Eastern Cape, 
Mpumalanga, Free State, Limpopo and Northern Cape Provinces. The majority of 
specimens received for P. jirovecii diagnosis were sputa (n = 839/932, 90%). 
When dealing with multiple specimens from the same patient and PCP episode, 
only the first P. jirovecii-positive specimen received in the laboratory was 
included in the analysis. If more than one specimen was taken on the same day, 
the specimen with the higher fungal load was included in the analysis. Data 
concerning HIV status, and prophylaxis and/or treatment for PCP were not 
available for these patients. All procedures followed were in accordance with the 
ethical standards of the Human Research Ethics Committee (Medical) of the 
University of the Witwatersrand in Johannesburg (Protocol no. M050320, 
Appendix G). 
 
2.3.3 Clinical Study (Chapter Five) 
Patients admitted to Chris Hani Baragwanath Hospital in Soweto, Johannesburg, 
South Africa, with clinically and radiologically suspected PCP (n = 268), were 
prospectively enrolled into the study from March 2005 through June 2009. A 
sample size calculation was performed based on the results of the laboratory 
study. A minimum of 250 patients would need to be screened to ensure at least 
25-30 patients in the double DHPS mutant M3 category. Informed written consent 
was obtained from each patient and all procedures followed were in accordance 
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with the ethical standards of the Human Research Ethics Committee (Medical) of 
the University of the Witwatersrand in Johannesburg (Protocol no. M040612, 
Appendix H). At enrolment, patients underwent sputum induction and were 
interviewed using a standard form (Appendix A). A single respiratory physician, 
who examined radiological films and completed a standard form for data 
collection, assessed almost all of the patients. Patients were monitored regularly 
during their hospital stay and data were recorded on the standard form (Appendix 
B). Patient treatment regimens were recorded throughout the study period, and the 
therapy of choice for PCP was co-trimoxazole (15-20 mg/kg/day trimethoprim 
and 75-100 mg/kg/day sulfamethoxazole for three weeks). Adjunctive 
corticosteroids (prednisone 40 mg bd for five days, then 40 mg daily for five days, 
followed by 20 mg daily for 11 days) were given to all patients who were treated 
for PCP. A telephonic and postal follow-up of discharged patients was conducted 
to ascertain their outcome at three months after their discharge (Appendices C and 
D).  
 
Patient features considered for statistical analysis were gender, age, CD4
+ 
cell 
count, newly diagnosed with HIV on admission, history of previous PCP, sulfa 
drug exposure, duration of hospital stay, development of pneumothorax, need for 
mechanical ventilation, respiratory failure and patient outcome. 
 
Sulfa drug exposure was defined as the use of any sulfa-based medication in the 
four months prior to admission. Patient outcome was classified as follows: died in 
hospital during the current admission, or discharged and died within three months 
after discharge, or alive at three months after discharge, or discharged but three-
month outcome was unknown. 
 
The respiratory samples were coded and all laboratory analyses were performed 
blind to the patient and clinical details. When dealing with multiple specimens 
from the same patient and PCP episode, the first P. jirovecii-positive specimen 
received in the laboratory was included in the analysis. If more than one specimen 
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was taken on the same day, the specimen with the higher fungal load was included 
in the analysis. 
 
2.3.4 Strain Characterization (Chapter Six) 
The first 40 HIV-positive patients enrolled in the prospective clinical study 
(Chapter Five) from March 2005 through March 2007, with specimens containing 
more than 100 P. jirovecii-DNA copies, were selected for ITS typing. Respiratory 
specimens containing less than 100 P. jirovecii-DNA copies were excluded, as the 
nested ITS PCR assay was not sensitive enough to reliably detect DNA in these 
samples. The specimens comprised 38 induced sputa and two bronchial washings. 
The respiratory samples were coded and all analyses were performed blind to the 
clinical details. 
 
2.4 Specimen Processing and Laboratory Diagnosis of P. jirovecii 
The accuracy of laboratory diagnosis was dependent upon successful sputum 
induction, as well as the presence of organisms in numbers above the limit of 
detection for the diagnostic methods. A standard sputum induction protocol was 
used to train the three study nurses and patient sampling was repeated if the 
sample volume was inadequate for laboratory diagnosis. 
 
Sputum specimens and other specimen types containing mucus were pre-treated 
with 0.1% dithiothreitol (Sigma-Aldrich, South Africa). After concentration by 
centrifugation, microscopic slides were prepared with the sediment. The 
remaining sediment was washed with phosphate-buffered saline and stored at -
70°C prior to DNA extraction. Slides were stained with a direct 
immunofluorescent antibody (IF) test specific for the detection of P. jirovecii 
cysts (Light Diagnostics, Millipore, Temecula CA), according to the 
manufacturer’s instructions. A positive IF result was defined as a specimen 
containing at least one cluster of P. jirovecii cysts with a characteristic 
morphology and fluorescent immunostain. An equivocal result was defined as a 
specimen with suspicious Pneumocystis-like cyst morphology, but not meeting 
the criteria to confirm a positive result. In our setting, IF microscopy had an 
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analytical sensitivity of 82.4% and specificity of 100% compared with the real-
time polymerase chain reaction (qPCR).  
 
2.5 DNA Extraction 
2.5.1 Pilot Study (Chapter Three) 
DNA was extracted from 50 µL of stored sediment, which was digested with 
proteinase K at 56°C for 2 hours, prior to extraction using the QIAamp DNA Mini 
Kit (Qiagen, Hilden, Germany), according to the manufacturer’s tissue protocol. 
Purified DNA was eluted in 100 µL of sterile water and stored at -20°C.  
 
2.5.2 DHPS Prevalence, Clinical and Strain Characterization Studies (Chapters 
Four, Five, Six) 
Genomic DNA was extracted from 50 µL of sediment, which was digested with 
proteinase K at 56°C for 2 hours, prior to automated DNA extraction with an M48 
BioRobot (Qiagen, Germany) according to the manufacturer’s soft tissue protocol. 
Purified DNA was eluted in 100 µL of sterile water and stored at -20°C.  
 
2.6 Determination of P. jirovecii DNA Load 
The amount of P. jirovecii DNA in specimens was determined by a quantitative 
real-time polymerase chain reaction (qPCR) targeting a portion of the 
mitochondrial gene coding for the large ribosomal subunit (mtLSU) of the fungus. 
This real-time PCR method had a lower limit of detection of 17 target gene 
copies/µL of extracted DNA. The following primers and probe were used: LSU1: 
5´-AAA TAA ATA ATC AGA CTA TGT GCG ATA AGG-3´; LSU2: 5´-GGG 
AGC TTT AAT TAC TGT TCT GGG-3´; LSUP1: FAM 5´-AGA TAG TCC 
AAA GGG AAA C-3´TAMRA (Applied Biosystems, Foster City, CA). 
Amplification reactions were carried out in a total volume of 25 µL containing 1x 
TaqMan Universal PCR Master Mix, 0.25 µL of a mixture of primers and probe at 
20 µM each, 5 µL of template DNA and RNase-free water to complete the 
volume. Thermal cycling was performed in an Applied Biosystems GeneAmp 
PCR System 7900 thermocycler as follows: 2 minutes at 50°C, 10 minutes at 
95°C, followed by 45 cycles of 15 seconds at 95°C and 1 minute at 60°C. 
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Quantification was based on extrapolation from standard curves generated by 
amplification of serial dilutions of a linearized pCR2.1 plasmid containing the 
P. jirovecii DNA fragment defined by primers LSU1 and LSU2. 
 
2.7 Analysis of DHPS Genotypes 
 
2.7.1 Pilot Study (Chapter Three) 
Amplification of a 300 bp region of the fas gene of P. jirovecii spanning the 
DHPS binding site was performed as previously described by Beard et al.
(119)
 In 
the first round of this PCR, the primers DHPS F1 (5' - CCT GGT ATT AAA CCA 
GTT TTG CC - 3') and DHPS B45 (5' - CAA TTT AAT AAA TTT CTT TCC 
AAA TAG CAT C-3') were used. In the second round, the primers DHPS AHUM 
(5' - GCG CCT ACA CAT ATT ATG GCC ATT TTA AAT C-3') and DHPSBN 
(5'- GGA ACT TTC AAC TTG GCA ACC AC - 3') were used. The primary 
amplification reaction contained 2 μl of template DNA, 1U of AmpliTaq Gold 
DNA polymerase (PE Applied Biosystems), 125 μM of each deoxynucleotide, 2 
mM MgCl
2 
and 1 μM each of primers in 1x PCR buffer (PE Applied Biosystems) 
and adjusted with RNase-free water to a total volume of 25 μl. The second 
amplification reaction contained the same concentration of reagents, and 2 μl of 
PCR product from the first reaction was included in the mixture. The 
amplification conditions for the first round were 93°C for 10 minutes, followed by 
35 cycles of 92°C for 30 seconds, 52°C for 30 seconds, 72°C for 60 seconds, and 
a final extension step at 72°C for 5 minutes. The amplification conditions for the 
second round of PCR were 93°C for 10 minutes, then 35 cycles of 92°C for 30 
seconds, 55°C for 30 seconds, and 72°C for 60 seconds, followed by a final 
extension step at 72°C for 5 minutes. PCR products were visualised by gel 
electrophoresis on 2% agarose gels. Nested PCR products, encompassing 
polymorphic nucleotide positions 165A/G and 171C/T, were directly sequenced 
using the BigDye Terminator sequencing kit (Applied Biosystems, Foster City, 
CA) and an Applied Biosystems model 310 automated DNA sequencer. 
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2.7.2 DHPS Prevalence Study (Chapter Four) 
Specimens with ≥20 target mtLSU gene copies/µL of extracted DNA were 
selected for DHPS analysis, as amplification of the single-copy DHPS fas gene 
proved to be less sensitive than the real-time PCR assay. Primers SMIF1: 5’-CAA 
ATT AGC GTA TCG AAT GAC C-3’ and SMIB2: 5’-GCA AAA TTA CAA 
TCA ACC AAA GTA-3’ were used to amplify a 1030 bp region of the DHPS 
gene. Subsequently, the nested primers SMIF6: 5’-AGC GCC TAC ACA TAT 
TAT GG-3’ and SMIB7: 5’-GTT CTG CAA CCT CAG AAC G-3’ were used to 
amplify a 278 bp region, encompassing polymorphic nucleotide positions 
165
A/G 
and 
171
C/T. The primary amplification reaction contained 5 μl of template DNA, 
1.25U of Taq polymerase (Invitrogen, Carlsbad CA), 200 μM of each 
deoxynucleotide, 3 mM MgCl
2 
and 1 μM each of primers in 1x PCR buffer 
(Invitrogen, Carlsbad CA), and adjusted with RNase-free water to a total volume 
of 25 μl. The second amplification reaction contained the same concentration of 
reagents, but only 1 μl of PCR product from the first reaction was included in the 
mixture. PCR amplification was performed in a Mastercycler Gradient (Eppendorf 
AG, Hamburg Germany) using the following conditions for the primary PCR: 
94°C for 5 minutes, followed by 35 cycles at 94°C for 30 seconds, 55°C for 1 
minute and 72°C for 2 minutes with a final extension at 72°C for 7 minutes. 
Nested PCR conditions were 94°C for 5 minutes, followed by 35 cycles at 94°C 
for 30 seconds, 52°C for 30 seconds and 72°C for 1 minute with a final extension 
at 72°C for 7 minutes. PCR products were visualised by gel electrophoresis on 2% 
agarose gels. Nested PCR products were sequenced using the primer SMIF6 and 
BigDye terminator chemistry. 
 
2.7.3 Clinical and Strain Characterization Studies (Chapters Five and Six) 
Amplification of a region of the fas gene of P. jirovecii spanning the DHPS 
binding site was performed as described in 2.7.2. Nested PCR products were 
directly sequenced using the primers SMIF6: 5’-AGC GCC TAC ACA TAT TAT 
GG-3’ and SMIB7: 5’-CTG CAA CCT CAG AAC G-3’ and BigDye terminator 
chemistry (Applied Biosystems, Foster City, CA). A second PCR reaction,
(119)
 as 
described in 2.7.1, was performed on those specimens that did not amplify with 
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the above set of primers. PCR products from specimens containing a mixture of 
P. jirovecii genotypes were ligated into pCR2.1-TOPO
® 
plasmid vectors from the 
TOPO TA Cloning Kit (Invitrogen, Carlsbad CA), according to the 
manufacturer’s instructions. Nine to ten independent clones per specimen were 
sequenced in both directions using the M13 primers and BigDye Terminator 
chemistry (ABI Prism 310 Genetic Analyzer, PE Applied Biosystems, Foster 
City, CA). 
 
2.8 Definitions of DHPS Genotypes 
The P. jirovecii wild-type (WT) genotype was defined as a DNA sequence with 
no substitutions at positions 165 and 171 in the fas gene, i.e. a threonine at DHPS 
amino acid position 55 and a proline at position 57. The mutant genotype M1 was 
defined as a sequence with a G substitution at position 165, M2 as a T substitution 
at position 171, and M3 as having substitutions at both positions. The observed 
mutations were all non-synonymous changes that resulted in amino acid 
substitutions at amino acid positions 55 and/or 57. Specimens containing a 
mixture of mutant and wild-type genotypes were classified in the mutant category. 
 
2.9 Analysis of ITS Haplotypes  
 
2.9.1 ITS PCR 
Amplification of the ITS1-5.8S-ITS2 region was performed as previously 
described by Lee et al 
(112)
 with modifications to reduce the formation of 
recombinants by Beser et al 
(114)
 The primary amplification reaction contained 5 
μl of template DNA, 1.25U of Taq polymerase (Invitrogen, Carlsbad CA), 200 
μM of each deoxynucleotide, 3 mM MgCl
2 
and 0.8 μM each of primers 1724F2 
(5’-AGT TGA TCA AAT TTG GTC ATT TAG AG-3’) and ITS2R (5’-CTC 
GGA CGA GGA TCC TCG CC-3’) in 1x PCR buffer (Invitrogen, Carlsbad CA) 
and adjusted with RNase-free water to a total volume of 25 μl. DNA amplification 
was carried out under the following conditions: 5 min at 94°C; followed by 10 
cycles of 1 min at 94°C, 1 min at 60°C, 4.3 min at 72°C; followed by 30 cycles of 
1 min at 94°C, 1 min at 60°C, 1.3 min at 72°C; and a final extension of 15 min at 
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72°C. The second amplification reaction (nested PCR) contained 2 μl of PCR 
product from the primary reaction, 1.25U of Taq polymerase, 200 μM of each 
deoxynucleotide, 1.5 mM MgCl
2
, 2 μM each of primers FX (5’-TTC CGT AGG 
TGA ACC TGC G-3’) and RT2 (5’-CTG ATT TGA GAT TAA AAT TCT TG-
3’) in 1X PCR buffer and adjusted with RNase-free water to a total volume of 25 
μl. Secondary amplification was performed under the following conditions: 5 min 
at 94°C; followed by 10 cycles of 1 min at 94°C, 1 min at 56°C, 4.3 min at 72°C; 
followed by 30 cycles of 1 min at 94°C, 1 min at 56°C, 1.3 min at 72°C; and a 
final extension of 15 min at 72°C. The amplified products were separated by gel 
electrophoresis on 1.2% agarose gels. Negative controls not containing template 
DNA were included in all reaction batches to monitor for contamination.  
 
2.9.2 Cloning and Sequencing of ITS PCR Products 
Nested PCR products were excised from the agarose gels and purified using a 
QIAquick Gel Extraction kit (Qiagen, Germany) according to the manufacturer’s 
instructions. The PCR products were ligated into pCR2.1-TOPO
® 
plasmid vectors 
from the TOPO TA Cloning Kit (Invitrogen, Carlsbad CA) according to the 
manufacturer’s instructions. Bacterial cells transformed by vectors not containing 
the PCR products expressed LacZ α-peptide and formed blue colonies in the 
presence of X-gal (Invitrogen, Carlsbad CA). Bacterial cells containing the PCR 
products did not express the LacZ α-peptide and formed white colonies. Screening 
of white bacterial colonies containing the PCR insert was performed with M13 
vector-specific primers in an amplification reaction mix containing 2.5U of Taq 
polymerase, 200 μM of each deoxynucleotide, 3 mM MgCl
2
, 0.2 ng/μl of each 
primer, in 1x PCR buffer and adjusted with RNase-free water to a final volume of 
20 μl. Bacterial clones were picked directly into the reaction mix and amplified 
under the following conditions: 5 min at 94°C; followed by 25 cycles of 30 sec at 
94°C, 30 sec at 45°C, 1 min at 72°C; and a final extension for 7 min at 72°C. The 
presence of cloned inserted PCR products was confirmed by gel electrophoresis 
on 1.2% agarose gels. Between nine to twelve independent clones per specimen 
were sequenced in both directions using the M13 primers and BigDye Terminator 
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chemistry (ABI Prism 310 Genetic Analyzer, PE Applied Biosystems, Foster 
City, CA). 
 
2.9.3 Determination of ITS Haplotypes 
The ITS1-5.8S-ITS2 sequences were edited, aligned and analyzed using the 
BioEdit Sequence Alignment Editor, version 7.0.4.1.
(120)
 A database was 
constructed with previously reported ITS sequences and study sequences were 
aligned with these using ClustalW software and the “best fit” was chosen  (Lee et 
al 
(112)
 GenBank accession numbers AF013806 to AF013834; Hosoya et al 
(121)
; 
Nimri et al 
(122)
 GenBank accession numbers AF374238 to AF374265; Matos et al 
(123)
 GenBank accession number AY390601; Nevez et al 
(124)
 GenBank accession 
number AF498265; Robberts et al 
(118)
 GenBank accession numbers AY328043 to 
AY328078 and AY330724; Totet et al 
(115)
 GenBank accession numbers 
AY135711 and AY135712; Siripattanapipong et al 
(116)
 GenBank accession 
numbers AY550105 to AY550109; van Hal et al 
(98)
 GenBank accession numbers 
EU442879 to EU442882; Beser et al 
(125)
 GenBank accession number EU527019 
and Gupta et al 
(126)
 GenBank accession numbers GU228517 to GU228519). 
Novel sequences were compared to published sequences using the NCBI 
nucleotide BLAST function.
(127)
 P. jirovecii ITS haplotypes were assigned 
according to the classification system of Lee et al. 
(112)
 The uppercase letter 
represented the ITS1 type and the lowercase letter represented the ITS2 type. 
Variations in the long homopolymeric thymine and adenine tracts were ignored in 
the determination of ITS type, as these have previously been reported as PCR-
induced errors.
(113)
 Sporadic single nucleotide changes were excluded from the 
analysis of sequence variation, as their significance and origin were uncertain. 
These sporadic changes were presumed to be PCR-generated errors if they 
occurred only once and in only one clone from a specimen. The anticipated error 
rate for the ITS1-5.8S-ITS2 region using Taq polymerase is known to be higher 
than that for introns and exons of the Trr1 gene (2.6 ±1.2 misincorporations/1000 
bp, with 12 558 bp sequenced vs 1.5 ±0.4 misincorporations/1000 bp, with 30 600 
bp sequenced).
(114)
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2.9.4 Nucleotide Sequence Accession Numbers 
The sequences of the novel ITS1 E variants SA1 and SA2 were deposited in 
GenBank with these respective accession numbers JN387046 and JN387047. 
 
2.10 Measures to Prevent Contamination of DNA  
Different rooms were used for the initial processing and immunostaining of 
specimens, DNA extraction, handling of template DNA, addition of PCR product 
to the nested reaction mix, sequencing steps and gel electrophoresis. A separate 
pre-PCR laboratory was used to prepare all PCR and sequencing master mixes. 
DNA was handled in a laminar flow cabinet equipped with a UV lamp for 
decontamination. Positive and negative controls were included with the DNA 
extraction process and PCR reactions. 
 
2.11 Data Analysis 
All clinical and laboratory investigations were performed blind to each other’s 
results. DNA sequences were analysed using BioEdit Sequence Alignment Editor 
Software version 7.0.9.0. Statistical analyses were performed with Excel and 
VassarStats Website for Statistical Computations.
(128)
 The Chi square
 
or Fisher 
exact tests were used to assess significant associations (P<0.05) among 
categorical variables. Continuous variables were compared using the Mann-
Whitney test when data were not distributed normally. A P value of less than 0.05 
was considered significant and tests were two-tailed. 
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C H A P T E R   T H R E E 
 
A PILOT STUDY TO INVESTIGATE THE PRESENCE OF DHPS 
POLYMORPHISMS IN SOUTH AFRICAN P. JIROVECII STRAINS 
 
Paper I: Published in 2006.
(129)
 Dini, L., du Plessis, M., Wong, M., Karstaedt, A., 
Fernandez, V. and Frean, J. Prevalence of DHPS polymorphisms associated with 
sulfa resistance in South African Pneumocystis jirovecii strains, J. Eukaryot. 
Microbiol., vol. 53(S1), 2006, pp. S110-S111 (Appendix E). 
 
3.1 Introduction 
Pneumocystis pneumonia (PCP) is a risk to a substantial proportion of the 
population of South Africa, in a setting of high HIV/AIDS prevalence, where 
HAART has been to a large extent unavailable.
(130)
 The South African 
government initiated the provision of HAART to the public sector in April 2004, 
but prior to that the HIV epidemic was largely untreated. By the end of 2006, 
HAART coverage was estimated at 21% of those needing antiretroviral 
therapy.
(131)
 The prevalence of HIV infection among prenatal clinic attendees in 
South Africa had risen dramatically from 0.7% in 1990 to 30.2% in 2005.
(132)
 In 
Gauteng Province, the estimated HIV prevalence in the total population was 
14.5% in 2006.
(133)
 In 2007, an estimated 5.7 million people were living with HIV 
infection out of a total population of 48.5 million, and 350 000 deaths were 
attributed to AIDS during the same year. 
(131)
 
 
An increased prevalence of DHPS point mutations has been associated with the 
use of trimethoprim-sulfamethoxazole (TMP-SMX), the drug of choice for the 
treatment and prophylaxis of PCP.
(66-67,84,134-136)
 This awoke concern for possible 
drug resistance in fungal strains. Prior to 2004 no studies had been conducted to 
assess the potential presence of DHPS polymorphisms in P. jirovecii strains from 
South Africa. A single study in 2003, based on a small sample size of 14 patients, 
had reported a prevalence of P. jirovecii DHPS mutations in 7% of Zimbabwean 
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HIV-infected adults with PCP. 
(100)
 Prior to 2003, no other studies investigating 
P. jirovecii DHPS polymorphisms had been published from developing countries. 
 
The aim of this pilot study was to investigate whether DHPS polymorphisms were 
present in P. jirovecii organisms in South Africa. 
 
3.2 Results and Discussion 
This is one of the first studies from South Africa investigating DHPS mutations in 
P. jirovecii organisms. A total of 79 respiratory specimens from 65 patients was 
successfully genotyped at the DHPS locus (Table 3). The prevalence of 
P. jirovecii containing DHPS mutations was 42% (27/65). Two other studies from 
South Africa with smaller sample sizes were published after we had analyzed our 
results. They reported much lower prevalences of DHPS mutations, 13% and 4% 
respectively.
(101-102)
 Robberts et al 
(102)
 detected a single M3 DHPS genotype in 
P. jirovecii from 53 PCP episodes. The study by Zar et al 
(101)
 enrolled 30 children 
from one hospital in the Western Cape Province. They found the M1 DHPS 
genotype in P. jirovecii from two children; the M2 genotype in P. jirovecii from 
one child and another child was infected with P. jirovecii containing the M3 
genotype. 
 
In this pilot study, P. jirovecii strains containing single DHPS mutations, either 
M1 or M2, were detected in 29% (19/65) of patients, and the double mutation M3 
was detected in P. jirovecii from 5 patients (8%). The most common DHPS 
mutation was M1, occurring in 18% (12/65) of P. jirovecii isolates. All five 
patients from the Eastern Cape Province were infected with P. jirovecii containing 
wild-type DHPS genotypes. The other three provinces had patients infected with 
wild-type and mutant P. jirovecii strains. Multiple specimens were available for 
13 patients and all except one patient had P. jirovecii with identical DHPS 
genotypes. This patient’s first specimen initially contained P. jirovecii with a 
wild-type DHPS genotype, and the second specimen taken two days later 
contained a mixture of wild-type and M1 DHPS genotypes. Fourteen percent 
(9/65) of specimens contained mixtures of P. jirovecii DHPS genotypes.  
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A limitation of our pilot study was the non-random selection of specimens, and a 
larger population-based study would be required to confirm the high prevalence of 
DHPS mutations in P. jirovecii organisms from South Africa. 
 
3.3 Conclusions 
This is one of the first studies from South Africa investigating DHPS mutations in 
P. jirovecii organisms. The prevalence of DHPS mutant genotypes was high at 
42%, and the most common DHPS mutant genotype was M1. P. jirovecii strains 
containing single DHPS mutations were detected in a third of patients, and 
mixtures of P. jirovecii genotypes were found in 14% of patient specimens. Based 
on the results of this pilot study, a decision was taken to proceed with a large 
prevalence study investigating DHPS polymorphisms in the general P. jirovecii 
population (Chapter Four), as well as a clinical study to ascertain their potential 
significance in patients with PCP (Chapter Five). 
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Table 3 P. jirovecii DHPS genotypes in respiratory specimens from South 
African patients 
DHPS genotype 
Nucleotide at position 
(amino acid) 
Proportion of 
patients (%) 
n = 65 165 (55) 171 (57) 
Wild-type (WT) A (Thr) C 
(105)
 38/65 (58) 
    
Mutant genotype, total   27/65 (42) 
    
Single mutation: position 165   12/65 (18) 
   M1 only G 
(37)
 C 
(105)
 7/65 (11) 
   M1 + WT G/A (Ala/Thr) C 
(105)
 5/65 (8) 
Single mutation: position 171  7/65 (11) 
   M2 only A (Thr) T (Ser) 6/65 (9) 
   M2 + WT A (Thr) T/C (Ser/Pro) 1/65 (2) 
    
Double mutation: 
  positions 165 + 171 (M3) 
G 
(37)
 T (Ser) 5/65 (8) 
    
Mixed genotypes
a
 G/A (Ala/Thr) T/C (Ser/Pro) 3/65 (5) 
a 
Mixed infections in which the presence of double DHPS mutants and wild-type  
and/or a mixture of single mutants could not be resolved 
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C H A P T E R   F O U R 
 
THE PREVALENCE OF P. JIROVECII DHPS MUTATIONS IN SOUTH 
AFRICA 
 
Paper II: Published in 2010.
(137)
 Dini, L., du Plessis, M., Frean, J. and Fernandez, 
V. High prevalence of dihydropteroate synthase mutations in Pneumocystis 
jirovecii isolated from patients with Pneumocystis pneumonia in South Africa, J. 
Clin. Microbiol., vol. 48 no. 6, June 2010, pp. 2016-2021 (Appendix F). 
 
4.1 Introduction 
The prevalence of P. jirovecii DHPS mutations reported from countries in the 
developed world ranges widely, from 4% to 81%.
(67,86-87,90,92,95,98,138)
 The few 
studies performed in developing countries all report low prevalences of 
P. jirovecii containing DHPS mutations.
(100,105-109)
 In South Africa, a handful of 
studies that screened specimens from limited numbers of adults and children have 
reported mostly low DHPS mutation rates.
(101-103)
 However, the results of the pilot 
study (Chapter Three), where 42% of specimens contained P. jirovecii with DHPS 
mutations, suggested that the prevalence of these mutations in the general 
population could be high. 
 
The aim of this large laboratory-based study was to ascertain the prevalence in 
South Africa of P. jirovecii strains in the population harbouring mutations at 
positions 165 and 171 in the fas gene. 
 
4.2 Results 
During the study period, from January 2006 through February 2007, 932 
respiratory specimens from 712 patients (93% >15 years of age) with suspected 
PCP were consecutively received for microbiological confirmation of P. jirovecii 
at the NICD in Johannesburg, South Africa. Immunofluorescence (IF) microscopy 
was positive for P. jirovecii in specimens from 168 (24%) patients. Table 4.1 
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provides the demographic details of the patients screened for P. jirovecii infection 
using IF microscopy. P. jirovecii DNA was detected in all of the IF-positive 
specimens from 150 patients that were available for assessment of fungal load 
using quantitative real-time PCR (qPCR). The quantity of P. jirovecii DNA 
measured in the first IF-positive specimen from each of these 150 patients is 
shown in Table 4.2. Microscopy was deemed equivocal for specimens from 14 
patients, and 10 of these yielded positive results with qPCR. Specimens from 530 
patients were IF-negative for P. jirovecii. Quantitative PCR was performed on a 
subset of IF-negative specimens from 191 patients that were arbitrarily chosen 
throughout the year. P. jirovecii DNA was detected and quantified in IF-negative 
specimens from 32 (17%) of these patients. 
 
Amplification of the DHPS gene of P. jirovecii was attempted in 201 specimens 
from 162 patients with a qPCR result of ≥20 target gene copies/µL of extracted 
DNA. The DHPS locus was successfully genotyped in a total of 183 specimens 
from 151 patients. Point mutations resulting in amino-acid substitutions Thr55Ala 
and/or Pro57Ser were detected in P. jirovecii from 85 (56%) patients (Table 4.3). 
Of these, 36 patients (42%) harboured P. jirovecii with either mutation Thr55Ala 
(19 patients, 22%) or Pro57Ser (17 patients, 20%). In specimens from 18 patients 
(21%) the presence of P. jirovecii organisms with both mutations in the DHPS 
gene could be ascertained. Specimens from 31 patients (36%) contained mixtures 
of mutant P. jirovecii DHPS genotypes, both with and without wild-type, which 
could not be resolved with direct sequencing. Infections with more than one 
DHPS genotype were detected in 69% (59/85) of patients harbouring mutant 
P. jirovecii.  Multiple respiratory specimens collected during the same PCP 
episode were available from 23 patients and the majority (17/23, 74%) presented 
identical DHPS genotypes. There were no significant differences in the frequency 
of wild-type or mutant DHPS genotypes between genders (P = 0.39), age groups 
(P = 0.38) or patients from distinct geographical locations (P = 0.1). 
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4.3 Discussion 
The primary aim of this study was to assess the prevalence in South Africa of 
P. jirovecii strains harbouring DHPS mutations previously shown to be associated 
with exposure to sulfa or sulfone drugs. The number of screened specimens and 
patients makes this study the largest of its kind conducted to date in the 
developing world. We found that 56% of PCP patients were infected with mutant 
P. jirovecii strains. This figure stands in contrast to the lower frequencies reported 
from the African continent and other countries outside of the industrialized 
world.
(100-103,105-107,109)
 The risk of P. jirovecii developing DHPS mutations is 
higher for PCP patients receiving sulfa prophylaxis than for those not receiving 
it.
(66-67,84-87)
 A general assumption is that the occurrence of DHPS mutations in 
developing countries is low due to a less extensive use of sulfa prophylaxis 
against PCP. Thus, the high frequency of DHPS mutations among PCP patients in 
South Africa would be indicative of a considerable exposure to sulfa medication, 
used either prophylactically against PCP or for treatment of other infections. We 
regard it as unlikely that sulfa (usually TMP-SMX) prophylaxis for PCP alone 
accounts for the high prevalence of mutant P. jirovecii observed in the present 
investigation. Although information regarding patient HIV status and use of 
prophylaxis was not available for this laboratory-based study, it is well recognized 
that a large proportion of HIV-positive patients in South Africa are either unaware 
of their HIV infection when they present with PCP or have limited access to 
prophylaxis. A large clinical study at a public hospital in Johannesburg showed 
that 58% of adult patients presenting with PCP were newly diagnosed with HIV, 
and only 16% of patients with a previously-confirmed HIV infection were 
receiving TMP-SMX prophylaxis (see Chapter Five). Furthermore, in a survey of 
South African primary level health care services for HIV-positive children, two-
thirds of public sector clinics did not have a policy in place for the administration 
of PCP prophylaxis.
(139)
 
 
The widespread use of sulfa drugs, particularly TMP-SMX, against diseases other 
than PCP could be contributing to the selection of P. jirovecii strains carrying 
mutations in the DHPS gene. In South Africa, guidelines issued by the 
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Department of Health have recommended the use of TMP-SMX to treat urinary 
tract infections, cholera, and acute otitis media at the primary care level, as well as 
invasive bacterial infections caused by Shigella and Salmonella species in 
hospitalised patients.
(99)
 Indications for HIV-positive individuals, apart from PCP 
prophylaxis and treatment, include prophylaxis against recurrent bacterial 
infections in children, prophylaxis against bacterial pneumonia, bacteraemia and 
isosporiasis in adults, as well as prophylaxis and treatment of toxoplasmosis. A 
2002 report revealed that 26% of primary health care clinics also administered 
TMP-SMX for acute respiratory and gastrointestinal tract infections in 
children,
(139)
 a finding in line with the generalized perception that sulfa-based 
drugs are often used in primary care as empiric treatment for a variety of 
conditions including diarrhoea and non-specific respiratory infections in adults 
and children. Extensive usage of TMP-SMX is known to exert considerable 
selective pressure on microbial populations and lead to the development of 
resistance.
(140-141)
 That this is the situation in Gauteng Province and other 
localities of South Africa is also suggested by the very high rates of TMP-SMX 
resistance consistently observed in surveillance isolates of pneumococcal and 
other bacterial species; for example, rates of TMP-SMX resistance in isolates of 
Streptococcus pneumoniae, Shigella spp and non-typhoidal salmonellae of over 
50%, 83% and 37% respectively, have been reported.
(142)
 Sulfadoxine-
pyrimethamine (Fansidar) was used as first-line treatment for malaria in South 
Africa until 2006; while the number of patients treated (between 1990 and 2006, 
an average of around 25 000 malaria cases per year) was relatively small in 
comparison to the burden of HIV-infected individuals, this may have contributed 
to selective pressure.  
 
The transmission of P. jirovecii strains is another factor that may influence the 
high prevalence of mutant DHPS strains observed in the present investigation. 
Airborne transmission of Pneumocystis spp. from host to host has been 
demonstrated in rodent models and numerous observations, including several 
cases of nosocomial clustering, suggest that direct or indirect transmission occurs 
in humans.
(51)
 Evidence for de novo acquisition of P. jirovecii with mutant DHPS 
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genotypes has been provided by studies including patients who had never received 
sulfa prophylaxis for PCP.
(65-66)
 In one of these studies, more than half of the 
patients newly diagnosed with HIV infection had mutant P. jirovecii.
(66)
 It is 
possible that inter-human transmission of P. jirovecii and concomitant circulation 
of DHPS genotypes in the population is accelerated in localities of South Africa 
with high HIV prevalence and large numbers of individuals with some degree of 
immunosuppression, from subclinical stages to overt AIDS, who are susceptible 
to colonization by the fungus. It is also possible that mutant strains have an 
inherent fitness that enables enhanced transmission. Widespread empiric use of 
TMP-SMX and increased transmission and circulation of strains/genotypes in the 
population could, at least in part, explain the high prevalence of mutant 
P. jirovecii in settings with limited implementation of PCP prophylaxis. 
 
Lack of clinical surveillance, unavailability of chest radiographic facilities and 
limited laboratory diagnosis contribute to the scarcity and disparity of information 
regarding burden of disease and epidemiology of PCP in African settings. In 
South Africa, collection of bronchoalveolar lavage (BAL) specimens is rare. The 
few specimens sent for laboratory confirmation are mostly sputa and these are 
often spontaneously expectorated rather than induced with hypertonic saline.
(143-
144)
 Although collection procedure was not specified for the majority of sputum 
specimen referrals in this study, we estimate that a high proportion were 
spontaneously expectorated. Clinically, it is accepted that BAL and induced 
sputum specimens are superior to spontaneously expectorated sputum for the 
microscopic diagnosis of PCP, in part, because many patients with PCP have a 
non-productive cough and cannot produce an adequate specimen without 
undergoing sputum induction. Whilst proper collection of the respiratory sample 
is of major importance for optimal laboratory diagnosis of PCP, it may also be 
crucial for the strain/genotype representativity of the specimen and the accurate 
assessment of mixed-genotype infections. In five out of a total of six cases with 
discrepant DHPS genotypes, we observed large differences (≥10-fold) in the 
quantity of P. jirovecii DNA measured in specimens from the same PCP episode 
showing non-identical DHPS genotypes. In some of these cases multiple samples 
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had been collected within 24 hours or less. This suggests that variable specimen 
quality, likewise initiation of PCP therapy, may be a cause of inconsistent results 
in the genotypic analysis of P. jirovecii infections. 
 
In South Africa, PCP has been studied more extensively in children and it is now 
recognised as a common pathogen in HIV-infected infants.
(42)
 In the present 
study, which predominantly includes specimens from adults, P. jirovecii infection 
was confirmed by IF microscopy in 24% of patients with suspected PCP. By 
quantitative real-time PCR analysis we could confirm P. jirovecii carriage in an 
additional 17% of patients with clinical PCP suspicion and negative IF 
microscopy. Detection of P. jirovecii was also verified by real-time PCR in 
specimens from 10 of 14 patients with equivocal microscopy results. Quantitative 
real-time PCR performed as a single-round amplification in a closed system offers 
the advantages of increased diagnostic sensitivity and rapidity with a reduced risk 
of contamination. Quantification of the level of P. jirovecii infection or 
colonization can be useful for monitoring therapy and the improved management 
of patients.
(145)
 Although increased diagnostic sensitivity carries a higher risk of 
clinically-false positives, it enhances the chances for early detection of 
biologically-true positives in individuals with no or incipient clinical 
manifestations, something that could be of critical importance in localities with 
high HIV incidence. 
 
This study has certain limitations. Data regarding HIV status, use of sulfa 
prophylaxis or other medication, and outcome of the patients were not available. 
These shortcomings, that preclude further analysis of possible underlying 
associations, expose the type of constraints that are common for laboratory-based 
studies. However, they do not have any bearing on the central issue of assessing 
the frequency of DHPS genotypes in P. jirovecii strains prevalent in the 
population. Although the study included patients from a large number of hospitals 
in South Africa, 57% of the patients with data on P. jirovecii DHPS genotypes 
came from two hospitals in Gauteng Province. 
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The increased risk of carrying mutant P. jirovecii DHPS genotypes in patients 
receiving sulfa prophylaxis suggests that mutations in the fas gene provide a 
selective advantage so that subpopulations of the fungus may eventually 
overcome the effects of prophylactic doses of TMP-SMX. The clinical 
significance of DHPS mutations and in particular whether single polymorphisms 
or a double mutation have differential effects on response to higher therapeutic 
doses are questions not yet resolved (see Chapter 5). The appearance of 
P. jirovecii strains with additional mutations and significantly higher levels of 
tolerance to sulfonamides and/or sulfones is a possibility that cannot be excluded. 
Examples of cumulative mutations leading to increased antibiotic resistance have 
been documented for viruses, bacteria and parasitic protozoa.  
 
4.4 Conclusions 
The number of screened specimens and patients makes this study the largest of its 
kind conducted to date in the developing world. P. jirovecii infection was 
confirmed by IF microscopy in 24% of patients with suspected PCP. Colonization 
by the fungus, characterized by IF-negative microscopy and low gene copy 
numbers in the real-time PCR, occurred in 17% of patients. The prevalence of 
infections with P. jirovecii containing DHPS mutations in adult South African 
patients is high at 56%. The results of this prevalence study confirmed the 
findings of the pilot study in Chapter Three, which reported a prevalence of 42% 
for P. jirovecii DHPS mutations. The frequencies of the different mutant DHPS 
genotypes were similar. P. jirovecii containing single DHPS mutations was found 
in 42% of patients and strains containing the double mutant M3 genotype were 
found in 21% of patients. Infections with more than one DHPS genotype were 
detected in 14% of patients. There were no significant differences in the 
proportions of wild-type or mutant P. jirovecii DHPS genotypes between genders, 
age groups or patients from distinct geographical locations. Widespread empiric 
use of TMP-SMX, as well as increased transmission and circulation of mutant 
DHPS strains/genotypes in the population could account for the high prevalence 
of mutant P. jirovecii in settings with limited implementation of PCP prophylaxis. 
It was therefore of great importance to proceed with a study to investigate the 
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potential clinical significance of these mutations in patients infected with this 
fungus (Chapter Five). 
 
 
 
Table 4.1 Comparison of patient demographic data between IF-positive and IF-
negative specimens, South Africa 
 
Variables 
 
Patients
a 
(n = 712) 
P. jirovecii immunofluorescence (IF) 
microscopy result 
IF-positive 
(n = 168) 
IF-negative 
(n = 544) 
Mean age ±SD (range) 34 ±13 (1m–86y) 33 ±10 (3m–66y) 34 ±13 (1m–86y) 
Female:male 1.6:1 1.8:1 1.6:1 
Province:    
     Gauteng  491 123 368 
     Eastern Cape  149 28 121 
     Mpumalanga  53 15 38 
     Free State  12 2 10 
     Limpopo  4 0 4 
     Northern Cape  3 0 3 
a 
93% of patients >15 years of age 
m month, y year 
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Table 4.2 Quantification of P. jirovecii DNA in respiratory specimens from 
patients with suspected Pneumocystis pneumonia 
Specimens 
   
Patients  
 
Real-time 
PCR-positive 
P. jirovecii DNA quantity 
     Median (range)
a
 
Sputum    
     IF-positive 140 140 3 062 (8 - 291 894) 
     IF-negative
b
 173 30 7 (1 - 499) 
     IF equivocal
c
 12 10 151 (9 - 1 549) 
    
Tracheal aspirate    
     IF-positive 7 7 1 921 (10 – 180 498) 
     IF-negative 4 1 1 
     IF equivocal 1 0  
   
Bronchoalveolar lavage   
     IF-positive 2 2 54 766 (3 – 109 529) 
     IF-negative 3 0  
    
Other
d
    
     IF-positive 1 1 299 
     IF-negative 11 1 4 
     IF equivocal 1 0  
IF immunofluorescence microscopy test 
a  
Expressed as target gene copies/µL of extracted DNA. Detailed information 
regarding handling of specimens and DNA extraction conditions is provided in 
the methods section. 
b 
A set of 205 specimens from 191 patients were arbitrarily chosen for qPCR 
analysis from the 530 patients with IF-negative results. 
c 
Immunofluorescence microscopy was suggestive of P. jirovecii, but not 
conclusive. 
d 
Includes 2 bronchial washings, 2 nasopharyngeal aspirates, 1 pleural fluid and 8 
samples with unknown specimen types. 
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Table 4.3 P. jirovecii DHPS genotypes in respiratory specimens from South 
African patients 
DHPS genotype 
Nucleotide at position (amino acid) No. patients (%) 
n = 151 
165 (55) 171 (57) 
Wild-type (WT) A (Thr) C 
(105)
 66/151 (44) 
    
Mutant genotype, total   85/151 (56) 
    
Single mutation   36/85 (42) 
   Position 165 (M1) G 
(37)
 C 
(105)
 4/85 (5) 
   M1 + WT G/A (Ala/Thr) C 
(105)
 15/85 (18) 
   Position 171 (M2) A (Thr) T (Ser) 7/85 (8) 
   M2 + WT A (Thr) T/C (Ser/Pro) 10/85 (12) 
    
Double mutation   18/85 (21) 
   Positions 165 + 171 (M3) G 
(37)
 T (Ser) 15/85 (18) 
   M3 + M1 G 
(37)
 T/C (Ser/Pro) 1/85 (1) 
   M3 + M2 G/A (Ala/Thr) T (Ser) 2/85 (2) 
    
Mixed genotypes
a
 G/A (Ala/Thr) T/C (Ser/Pro) 31/85 (36) 
a 
Mixed infections in which the presence of double mutants and wild-type and/or a 
mixture of single mutants could not be resolved. 
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C H A P T E R   F I V E 
 
OUTCOME OF HIV-POSITIVE SOUTH AFRICAN PATIENTS WITH 
PNEUMONIA CAUSED BY P. JIROVECII WITH AND WITHOUT DHPS 
GENE MUTATIONS 
 
Paper III: Manuscript in preparation. Dini, L., Wong, M., Frean, J., du Plessis, 
M., and Karstaedt, A. Effect of Pneumocystis jirovecii dihydropteroate synthase 
gene mutations on outcome of South African patients with HIV: a prospective 
study. 
 
5.1 Introduction 
After establishing that the prevalence of P. jirovecii DHPS mutations 
corresponding to the DHPS binding site was high (56%) in South Africa (Chapter 
Four), a large prospective clinical study was launched to investigate the 
significance of these polymorphisms in patients suffering from PCP. The clinical 
significance of P. jirovecii DHPS mutations is not fully understood and results are 
conflicting. One study 
(67)
 found a significantly lower three-month survival in 
patients harbouring mutant P. jirovecii, whilst two other studies 
(84,93)
 found no 
significant association between patient survival and DHPS genotype at four and 
six weeks respectively. Huang et al 
(90)
 found an insignificant trend for patients 
harbouring mutant P. jirovecii DHPS to have an increased mortality, whilst 
Nahimana et al 
(86)
 had similar in-hospital rates of death for patients with or 
without mutant P. jirovecii. Crothers et al 
(87)
 found that mortality was not 
associated with the presence of DHPS mutations. The majority of clinical studies 
found an association between sulfa prophylaxis and the presence of DHPS 
mutations.
(66-67,84,86-87,90-91)
 Whilst two studies, with low numbers of patients 
infected with mutant P. jirovecii, reported no association with sulfa prophylaxis 
and mutant DHPS genotype. 
(92,96)
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The aim of this large, prospective, clinical study was to ascertain the clinical 
significance of P. jirovecii strains harbouring mutations at positions 165 and 171 
in the fas gene. 
 
5.2 Results 
From March 2005 through June 2009, 306 respiratory specimens from 266 adult 
patients with clinically and/or radiologically suspected PCP were screened for 
P. jirovecii infection. All patients were confirmed HIV-positive or were clinically 
strongly suspected of AIDS. Immunofluorescence (IF) microscopy was positive 
for P. jirovecii in specimens from 150 patients (56%). Microscopy was deemed 
equivocal for specimens from 11 patients; four of which yielded positive results 
with quantitative real-time PCR (qPCR). P. jirovecii DNA was detected by 
quantitative real-time PCR in specimens from 189 patients (71%), and the median 
fungal load was 837 target gene copies/µL of extracted DNA (range: 2-704 257). 
 
Prevalence of DHPS genotypes 
The DHPS locus was successfully genotyped in specimens from 161 patients 
(85%). DHPS amplification was not always successful in specimens with fungal 
loads of less than 170 target gene copies/µL of extracted DNA. Point mutations 
resulting in amino acid substitutions Thr55Ala and/or Pro57Ser were detected in 
P. jirovecii strains from 98 patients (61%) (Table 5.1). Of these, 57 patients (58%) 
harboured P. jirovecii with single DHPS mutations. The frequency of mutation 
M1 was 26% (25/98) and M2 was 56% (55/98). The double mutation M3 was 
present in specimens from 41 patients (42%). P. jirovecii infections with more 
than one DHPS genotype were detected in 47% (75/161) of patients. Specimens 
containing multiple ambiguous genotypes were cloned and sequenced to resolve 
the mixtures. Specimens containing mixtures of wild-type and mutant DHPS 
strains were classified into the mutant category. The proportion of mutant DHPS 
genotypes stayed relatively stable over the study period, except in 2007 where it 
dropped to 44% (Figure 5). 
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Multiple respiratory specimens collected during the same PCP episode were 
available from 10 patients and six (60%) presented with identical DHPS 
genotypes (Table 5.2, patients 1 to 10). No genotype switching occurred in the 
other four patients, but an additional genotype was detected in each case. In two 
patients the additional DHPS genotype was detected in specimens with a higher 
fungal load, suggesting that the additional genotype was present at a lower 
frequency than the original genotypes. DHPS sequences from patient 2 were 
cloned and sequenced and the additional genotype M2 occurred at a lower 
frequency than the original genotypes. One patient (patient 11 in Table 5.2) was 
admitted twice for PCP, with episodes separated by six months. This patient 
initially presented with a mixture of wild-type, M1 and M2 genotypes, which 
were resolved by cloning and sequencing of PCR products. During the second 
admission an M3 genotype was detected in addition to the wild-type genotype. 
 
Association between DHPS mutations and sulfa exposure 
Patient demographics, clinical characteristics and outcome are provided in Table 
5.3. According to patient interview, only five patients had a previous history of 
PCP and 26 patients (16%) were exposed to sulfa in the four months prior to 
admission. There were no significant associations between the presence of DHPS 
mutations and previous PCP (P = 0.37) or exposure to sulfa-based medication (P 
= 0.34). In our study 57 of the 98 patients (58%), who were newly diagnosed with 
HIV on admission, harboured P. jirovecii with mutant DHPS genotypes. 
 
Outcome of patients infected with PCP according to DHPS genotype 
Significantly more patients infected with mutant P. jirovecii DHPS genotypes 
died in hospital compared with patients infected with wild-type DHPS genotypes 
(26/98, 27% versus 8/63, 13%, P = 0.04) (Table 5.3). The overall in-hospital 
mortality was 21% (34/161). The median stay in hospital was 10 days and was 
similar for patients in the DHPS mutant and wild-type groups. There were no 
significant associations between DHPS genotype and patient gender, age, CD4
+
 
count, diagnosis of HIV on admission, pneumothorax, need for mechanical 
ventilation, or respiratory failure. When examining the different mutant DHPS 
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genotypes, there were no significant associations in patients harbouring 
P. jirovecii with single DHPS mutations (genotypes M1 and M2) compared with 
those infected with the double mutant M3 genotype (Table 5.4). However, there 
was an insignificant trend for patients infected with the M3 genotype to have a 
lower median CD4
+
 cell count compared to patients harbouring strains with single 
mutations (P = 0.06). In-hospital mortality was similar for patients infected with 
P. jirovecii containing single DHPS mutant genotypes compared with double 
mutant genotypes (18/57, 32% versus 8/41, 20%).  
 
Patients that survived (79%) were either discharged home well, referred to a TB 
treatment facility or to a step-down clinic for further treatment. A telephonic 
and/or postal follow-up was conducted to assess the mortality of patients at three 
months after discharge, and the response rate was 70% (89/127). When assessing 
the mortality of only the discharged patients at three months, significantly more 
patients died of wild-type P. jirovecii strains than those infected with mutant 
strains (9/63, 14% versus 4/98, 4%, P = 0.02). The overall mortality rate of the 
discharged patients at three months was 15% (13/89). When combining in-
hospital patient mortality and mortality at three months after discharge, the 
mortality rate was 38% (47/123) and there were no significant associations with a 
DHPS genotype (P = 0.82), nor with a particular mutant genotype (P = 0.12). 
 
5.3 Discussion 
This study is unique in the developing world as it was conducted prospectively 
and has a large sample size, especially in the P. jirovecii mutant DHPS category. 
The primary aim of this study was to assess the clinical significance in South 
Africa of P. jirovecii strains harbouring DHPS mutations previously shown to be 
associated with exposure to sulfonamide drugs. The majority of patients (61%) 
harboured mutant P. jirovecii strains, a result which is consistent with the 
prevalence of 56% reported from our previous study 
(137)
(Chapter Four). The 
proportion of mutant DHPS genotypes stayed relatively stable over the study 
period. The most frequent DHPS mutant genotype was M2, which has a single 
point mutation at nucleotide position 171 in the fas gene, followed by the double 
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mutant genotype M3, which has single nucleotide point mutations at positions 165 
and 171. Multiple P. jirovecii infections were found in 47% of patients. 
 
The in-hospital mortality was higher than the mortality of the discharged patients 
at 3 months. Significantly more patients died in hospital of P. jirovecii containing 
mutant DHPS genotypes than those infected with wild-type strains (P = 0.04). 
Our study is one of the few to show an association between mutant DHPS 
genotypes and increased in-hospital mortality. A study from Italy with a low 
prevalence of mutant genotypes also showed a correlation between DHPS mutants 
and worse outcomes.
(92)
 Crothers et al 
(87)
 found that patients infected with mutant 
P. jirovecii strains tended to have worse outcomes than those infected with wild-
type strains. Helweg-Larsen et al 
(67)
 found that the presence of DHPS mutations 
was the most important predictor of mortality. 
 
Interestingly, mortality at three months among the discharged patients was 
associated with the wild-type DHPS genotype. This result could not have been 
affected by the relative proportions of DHPS genotypes in the discharged patient 
group, as more patients were infected with mutant P. jirovecii than wild-type 
(61% versus 39%). However, 30% of discharged patients were lost to follow up 
and their results may have an effect on the mortality figure. The prevalence of 
mutant P. jirovecii in these patients compared with wild-type was 18% versus 
32%. It was not possible to ascertain if the patients died of P. jirovecii infection 
within the three months after discharge. An autopsy study from South Africa 
showed that one third of patients with P. jirovecii infections were co-infected 
another pathogen.
(40)
 Co-infections with other pathogens contribute to the 
morbidity and mortality of patients with PCP. 
 
When combining in-hospital mortality and mortality at three months after 
discharge, there were no significant associations with a particular DHPS 
genotype. These results appear to be conflicting, but assessing if a patient’s 
outcome is due entirely to the presence or absence of DHPS mutations is very 
difficult. The assessment of a patient’s outcome is complex, because many factors 
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can affect outcome, such as co-infections with other pathogens, underlying health 
conditions, severity of disease, and adherence to treatment. Crothers et al 
(87)
 
suggested that mortality in most HIV-infected patients with PCP was related 
primarily to the underlying severity of illness and the initial severity of PCP, even 
though they found a trend towards worse outcomes in patients with mutant 
P. jirovecii. 
 
There were no significant associations between the presence of DHPS mutant 
genotypes and previous PCP or exposure to sulfa medication. However, very few 
patients (3%) reported a previous PCP episode and only 16% of patients had been 
exposed to any sulfa-based medication in the four months prior to admission, 
according to patient recall. One patient who had a previous PCP episode 
developed an M3 (double mutant) genotype during his second PCP episode six 
months later. Our data support the hypothesis that P. jirovecii strains with mutant 
DHPS genotypes may be transmitted from person to person, as 58% of the 
patients diagnosed with HIV on admission harboured P. jirovecii with mutant 
DHPS genotypes. Several studies have reported patients harbouring P. jirovecii 
strains with mutant genotypes, who had not been exposed to sulfa drug 
prophylaxis.
(65-66,91,96)
  
 
This study has certain limitations. Some patients could not provide clear 
information as to their use of sulfa-based medication prior to admission. Patient 
adherence to treatment could not easily be monitored. The patient outcome results 
at three months post-discharge may be affected by the fact that 30% of patients 
(38/127) were lost to follow-up. 
 
 
5.4 Conclusions 
This study is unique in the developing world as it was conducted prospectively 
and has a large sample size, especially in the mutant DHPS category. 
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5.4.1 Prevalence of DHPS Genotypes 
The majority of patients (61%) harboured mutant P. jirovecii strains, a result 
which is consistent with the 56% reported from the prevalence study (Chapter 
Four). The proportion of mutant DHPS genotypes stayed relatively stable over the 
study period. Multiple P. jirovecii infections were found in 47% of patients. The 
most frequent DHPS mutant genotype among patient specimens was M2 followed 
by M3. 
 
5.4.2 Inter-human Transmission 
Few patients were exposed to sulfonamides prior to their admission, and almost 
60% of the patients diagnosed with HIV on admission harboured P. jirovecii with 
mutant DHPS genotypes. Inter-human transmission of P. jirovecii carrying mutant 
DHPS genotypes could, at least in part, explain the high prevalence of DHPS 
mutations in adult HIV-positive South Africans. 
 
5.4.3 Clinical Significance of DHPS Mutant Genotypes 
The in-hospital mortality was higher than the mortality of the discharged patients 
at three months. Significantly more patients died in hospital of P. jirovecii 
containing mutant DHPS genotypes than those infected with wild-type strains (P 
= 0.04). Our study is one of the few to show an association between mutant DHPS 
genotypes and increased in-hospital mortality. Mortality at three months among 
the discharged patients was associated with the wild-type DHPS genotype. 
However, cause of death in these patients was unknown. There were no 
significant associations in patients harbouring P. jirovecii with single DHPS 
mutations (genotypes M1 and M2) compared with those infected with the double 
mutant M3 genotype. However, there was an insignificant trend for patients 
infected with the M3 genotype to have a lower median CD4
+
 cell count compared 
to patients harbouring strains with single mutations (P = 0.06). 
 
The next chapter (Chapter Six) focuses on a subgroup of patients from this 
clinical study and characterizes the P. jirovecii strains in these patients based on 
ITS typing. 
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Figure 5 The proportion of mutant DHPS genotypes per year in 161 patients 
infected with Pneumocystis jirovecii (n = total number of patients) 
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Table 5.1 P. jirovecii DHPS genotypes in respiratory specimens from 161 South 
African patients 
DHPS genotype 
Nucleotide at position  
(amino acid) 
No. patients (%) 
n = 161 
165 (55) 171 (57) 
Wild-type (WT) A (Thr) C 
(105)
 63/161 (39%) 
    
Mutant genotype, total   98/161 (61%) 
   
Single mutation: position 165  15/98 (15) 
   M1 only G 
(37)
 C 
(105)
 0 
   M1 + WT G/A (Ala/Thr) C 
(105)
 15/98 (15) 
Single mutation: position 171  39/98 (40) 
   M2 only A (Thr) T (Ser) 11/98 (11) 
   M2 + WT A (Thr) T/C (Ser/Pro) 28/98 (29) 
Single mutations: positions 165 + 171  3/98 
(140)
 
   M1 + M2 + WT
a
 G/A (Ala/Thr) T/C (Ser/Pro) 3/98 
(140)
 
Double mutation: positions 165 + 171   41/98 (42) 
   M3 only G 
(37)
 T (Ser) 12/98 (12) 
   M3 + WT
a
 G/A (Ala/Thr) T/C (Ser/Pro) 12/98 (12) 
   M3 + M1 G 
(37)
 T/C (Ser/Pro) 2/98 (2) 
   M3 + M1 + WT
a
 G/A (Ala/Thr) T/C (Ser/Pro) 2/98 (2) 
   M3 + M2 G/A (Ala/Thr) T (Ser) 5/98 (5) 
   M3 + M2 + WT
a
 G/A (Ala/Thr) T/C (Ser/Pro) 5/98 (5) 
   M3 + M1 + M2
a
 G/A (Ala/Thr) T/C (Ser/Pro) 2/98 (2) 
   M3 + M1 + M2 + WT
a
 G/A (Ala/Thr) T/C (Ser/Pro) 1/98 (1) 
a
 Mixed genotypes were resolved by cloning and sequencing 
WT wild-type, M1 mutation 1, M2 mutation 2, M3 mutation 3 
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Table 5.2 Comparison of DHPS genotypes in 11 patients with multiple specimens 
Patient 
no. 
Specimen Sampling 
interval 
Fungal 
load
a
 
DHPS 
genotype 
Cloning result
b
 
1 1 2 days 33 825 WT  
 2  156 WT  
      
2 1 2 days 12 270 WT+M3+M2 WTx7, M3x2, M2x1  
 2  192 794 WT+M3 WTx8, M3x2 
      
3 1 1 day 2 566 M2  
 2  388 M2+WT  
      
4 1 1 day 585 WT  
 2  475 WT  
      
5 1 2 days 873 M3+M2  
 2  45 M3  
      
6 1 3 days 134 M2+WT  
 2  649 M2+WT  
      
7 1 2 days 202 WT  
 2  1 085 WT  
      
8 1 3 days 826 M1+WT  
 2  939 M1+WT  
      
9 1 2 days 401 WT  
 2  1 705 WT+M2  
      
10 1 2 days 396 WT  
 2  1 714 WT  
      
11 1 6 months 8 568 M2+WT+M1 M2x6, WTx3, M1x1 
 2  83 596 WT+M3 WTx6, M3x3 
a
 Expressed as target gene copies/µL of extracted DNA 
b
 Specimens containing mixtures of DHPS genotypes were resolved by cloning 
and sequencing 
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Table 5.3 Demographic, clinical characteristics and outcome of 161 PCP patients 
according to DHPS genotypes  
 
Characteristic 
DHPS genotype  
P 
value Mutant
a
 
(n = 98) 
Wild-
type 
(n = 63) 
Gender: Female, No. of patients (%) 78 (80%) 42 (67%) 0.07
c
 
Mean age, years ±SD (range) 36 ±8 
(20-58) 
34 ±9 
(19-56) 
0.10
e
 
Median CD4
+
 cell count, cells/mm
3
 (range) 18 
(1-226) 
26 
(1-470) 
0.20
e
 
Newly diagnosed with HIV on admission, No. 
of patients (%) 
57 (58%) 41 (65%) 0.38
c
 
History of previous PCP, No. of patients (%) 4 (4%) 1 (2%) 0.65
d
 
Sulfa/sulfone exposure
b
, No. of patients (%) 18 (18%) 8 (13%) 0.34
c
 
Median hospital stay, days (range) 10 (2-42) 10 (3-34) 0.48
e
 
Development of pneumothorax, No. of patients 
(%) 
4 (4%) 2 (3%) 1.0
d
 
Mechanical ventilation necessary, No. of 
patients (%) 
4 (4%) 2 (3%) 1.0
d
 
Respiratory failure, No. of patients (%) 87 (89%) 55 (87%) 0.78
c
 
    
Outcome:    
Death in hospital, No. of patients (%) 26 (27%) 8 (13%) 
0.04
c
 
Discharged, No. of patients (%) 72 (73%) 55 (87%) 
Discharged, alive after 3 months, No. of patients 
(%) 
50 (51%) 26 (41%) 
0.02
c
 
Discharged, death within 3 months, No. of 
patients (%) 
4 (4%) 9 (14%) 
3-month outcome unknown, No. of patients (%) 18 (18%) 20 (32%)  
a 
Specimens containing mixtures of wild-type plus mutant DHPS genotype were 
classified into the mutant category after cloning and sequencing. 
b 
Use of any sulfa-based medication in the 4 months prior to admission. 
c
 Chi square test, 
d
 Fisher exact test, 
e
 Mann-Whitney test, considered significant 
at the 5% level if P<0.05 
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Table 5.4 Demographic, clinical characteristics and outcome of 98 PCP patients 
according to mutant DHPS genotype 
Characteristic Single 
mutation 
M1 and/or 
M2 
(n = 57) 
Double
a 
mutation 
M3 
(n = 41) 
P 
value 
Gender: Female, No. of patients (%) 44 (77%) 34 (83%) 0.49
c
 
Mean age, years ±SD (range) 37±8 
(21-58) 
35±8 
(20-54) 
0.16
e
 
Median CD4
+
 cell count, cells/mm
3
 (range) 20 
(3-184) 
12 
(1-226) 
0.06
e
 
Newly diagnosed with HIV on admission, No. 
of patients (%) 
37 (65%) 20 (49%) 0.11
c
 
History of previous PCP, No. of patients (%) 1 (2%) 3 (7%) 0.30
d
 
Sulfa/sulfone exposure
b
, No. of patients (%) 9 (16%) 7 (17%) 0.87
c
 
Median hospital stay, days (range) 10 (2-26) 9 (2-42) 0.47
e
 
Development of pneumothorax, No. of patients 
(%) 
3 (5%) 1 (2%) 0.64
d
 
Mechanical ventilation necessary, No. of 
patients (%) 
3 (5%) 1 (2%) 0.64
d
 
Respiratory failure, No. of patients (%) 49 (86%) 38 (93%) 0.35
d
 
    
Outcome:    
Death in hospital, No. of patients (%) 18 (32%) 8 (20%) 
0.18
c
 
Discharged, No. of patients (%) 39 (68%) 33 (80%) 
Discharged, alive after 3 months, No. of 
patients (%) 
25 (44%) 22 (54%) 
0.37
d
 
Discharged, death within 3 months, No. of 
patients (%) 
4 (7%) 1 (3%) 
Three-month outcome unknown, No. of 
patients (%) 
10 (18%) 10 (24%)  
a 
Specimens containing mixtures of M3+M1/M2 were classified into the M3 
category. 
b 
Use of any sulfa-based medication in the 4 months prior to admission 
c 
Chi square test, 
d
 Fisher exact test, 
e
 Mann-Whitney test, considered significant 
at the 5% level if P<0.05 
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C H A P T E R   SIX 
 
STRAIN CHARACTERIZATION OF P. JIROVECII BASED ON ITS 
TYPING 
 
Paper IV: Manuscript in the final stage before submission. Dini, L., Beser, J. and 
Wong, M. Characterization of Pneumocystis jirovecii strains from South Africa 
based on nucleotide sequence variations in the internal transcribed spacer regions 
of rRNA genes. 
 
6.1 Introduction 
The aim of this component of the research was to characterize the P. jirovecii 
strains present in respiratory specimens from a subset of patients enrolled in the 
prospective clinical study described in Chapter Five. A secondary aim was to 
investigate possible correlations between different strains and a particular clinical 
feature, DHPS genotype or patient outcome. Characterization of P. jirovecii 
strains in this study was performed by analysis of sequence variation in the 
internal transcribed spacer (ITS) regions in the nuclear rRNA gene complex. The 
ITS regions show great diversity among Pneumocystis strains and provide an 
informative epidemiological tool for the typing of these strains.
(110)
  
 
6.2 Results 
The ITS1-5.8S-ITS2 region was successfully amplified, cloned and sequenced in 
specimens from 40 HIV-positive patients. A total of 11 different bona fide ITS 
haplotypes were detected; six ITS1 types and nine ITS2 types, all of which had 
been previously described. The majority of patients (85%, 34/40) were infected 
with P. jirovecii possessing an Eg ITS haplotype, either singly or in combination 
with another ITS haplotype (Table 6.1).  Eg was present as a single infection in 
43% (17/40) of patients. The frequency of multiple ITS haplotype infections in 
patients was 48% (19/40), which made cloning of PCR products prior to 
sequencing necessary. At least ten clones per specimen were sequenced in both 
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directions. The second most common ITS haplotype was Eu, which was found in 
13% (5/40) of patients, and occurred as a single infection in 3% (1/40) of them. 
The Eu haplotype has previously been reported in specimens from South African 
patients at a frequency of 16%.
(118)
 Three ITS haplotypes, Em, Ec, and Eb, were 
each found in 10% of patients, and both Ec and Eb occurred as single infections in 
3% of patients. Three ITS haplotypes, Bi, Gg and Ep each occurred in 8% (3/40) 
of patients, but only Gg was found as a single infection in 3% of patients. The ITS 
haplotype Fu4, previously reported by Hosoya et al 
(121)
 in patients from Japan, 
occurred in 5% (2/40) of patients and was not found as a single infection. The ITS 
haplotypes Ne and Ai were present in 3% (1/40) of patients and did not occur as 
single infections. The haplotypes Ei, Au, Eu4, Fe, Ee, Ng and Cg were considered 
to be possible recombinant or artifactual haplotypes. This assumption was based 
on the low frequency of these haplotypes, their unusual association with an ITS1 
or ITS2 type, the lack of single infections, and their consistent presence as mixed 
infections with other accepted more common haplotypes. The generation of 
artifactual haplotypes by the actual PCR method was proven by Beser et al.
(114)
 
 
Two novel ITS1 sequences, SA1 and SA2, were detected in patient specimens 
(Table 6.1) and no exact matches were found when the sequences were blasted 
against published sequences in the NCBI database. Both SA1 and SA2 showed 
most similarity to ITS1 type E and both were combined with a g in the ITS2 type. 
Figures 6.2 and 6.3 show SA2 and SA1 aligned with ITS1 type E respectively. 
SA2 had an AT deletion at position 113 and a T insertion at position 145 in Figure 
6.2, and SA1 had an A insertion at position 17 in Figure 6.3. Sporadic single 
polymorphisms were ignored, as well as variable lengths of homopolymeric 
thymine tracts at nucleotide positions 66-67. These were presumed to be PCR-
generated errors. According to Lee’s (112) definition, SA1 and SA2 were not 
considered as new distinct ITS1 types, as they were not found in two or more 
specimens. SA1 was identified in eight clones of P. jirovecii isolated from a 
single patient and the other four clones were Eg. SA2 was identified from ten 
clones of P. jirovecii isolated from another patient and the other two clones were 
Gg. 
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Table 6.2 describes the P. jirovecii ITS haplotypes and their corresponding DHPS 
genotype that occurred in specimens from each of the 40 study patients. The 
maximum number of combined ITS haplotypes in a single patient was five, and 
this particular patient had clones with recombinants that could have arisen from a 
hidden Ne haplotype (see patient 13 in Table 6.2). Point mutations resulting in 
amino-acid substitutions Thr55Ala and/or Pro57Ser were detected in P. jirovecii 
strains from 24 patients (60%). P. jirovecii with single DHPS mutations were 
found in 19 patients (48%). The frequency of mutation M1 was 8% (3/40) and M2 
was 40% (16/40). The double mutation M3 was present in specimens from 11 
patients (28%). Infections with more than one DHPS genotype were detected in 
40% (16/40) of patients. Specimens containing mixtures of wild-type and mutant 
DHPS strains were classified into the mutant category. 
 
Thirty patients had specimens with either a single ITS haplotype or a single DHPS 
genotype, enabling an analysis of potential associations between them. The 
prevalence of DHPS genotypes in these 30 patients was 73% wild-type, 27% M2 
single mutation, 20% M3 double mutation and 3% M1 single mutation. When 
comparing ITS haplotype with DHPS genotype, three combinations had a higher 
than expected prevalence (50%) of mutant genotypes (Table 6.3): Eb with M2, Bi 
with M3, and Gg with M3.  
 
Patient demographics, clinical characteristics and outcome are provided in Table 
6.4. Only 21 patients (53%) were infected with P. jirovecii of a single ITS 
haplotype. There were no obvious associations between ITS haplotype and a 
particular clinical characteristic or outcome. 
 
6.3 Discussion 
The P. jirovecii strains present in respiratory specimens from a subset of patients 
enrolled in the prospective clinical study were characterized by ITS typing. A 
total of 11 different bona fide ITS haplotypes, six ITS1 and nine ITS2 types, were 
found in P. jirovecii isolated from 40 HIV-positive patients in South Africa. As 
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with the majority of studies from other countries, the global ITS haplotype Eg was 
most prevalent among P. jirovecii infecting HIV-positive patients in South Africa. 
This haplotype occurred at a high frequency of 85% in the South African isolates, 
and is the highest reported frequency of Eg to date. This study confirmed the 
presence of the local South African haplotype Eu. Two ITS haplotypes, Fu4 and 
Ep, that had previously only been reported in Japan were also found in South 
Africa.
(121,146)
 The ITS2 type p was first described in Thailand, where it was 
linked with the ITS1 types I and R.
(116)
 The frequency of Ne in the South African 
samples was extremely low and is in keeping with an earlier study from South 
Africa.
(118)
 The ITS haplotype Ea, previously reported to occur in South Africa 
was absent in specimens from this study. The two novel ITS1 sequences SA1 and 
SA2 are likely variations of type E. It remains to be seen if these variants are 
novel ITS1 types and if their occurrence is local or global.  
 
There were no obvious associations between ITS haplotype and a particular 
clinical characteristic or patient outcome. However, the groups of patients with a 
single ITS haplotype infection were often too small to perform statistical analyses. 
Helweg-Larsen et al, 2001 found no association of ITS haplotypes with clinical 
severity of PCP in 130 patients.
(117)
 
 
The prevalence of mutant DHPS P. jirovecii strains among this group of patients 
was 60%, which is consistent with the prevalence of 56% reported from our 
previous study.
(137)
 The most frequent DHPS mutant genotype was M2, which has 
a single point mutation at nucleotide position 171 in the fas gene. Genotype M2 
had a higher than expected prevalence in specimens with the P. jirovecii ITS 
haplotype Eb, suggesting a possible association between them. In addition, the 
double mutant M3, had a higher than expected prevalence in specimens with the 
ITS haplotypes Bi and Gg. Despite the fact that the vast majority (85%) of 
specimens contained P. jirovecii with an Eg haplotype and 60% of specimens 
contained a mutant DHPS genotype, Eg strains were more often associated with a 
wild-type DHPS genotype. This was also the case for the ITS haplotypes Eu, Ec, 
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Fu4 and Ep. Meshnick et al, 2001 found that Ne, Eg and Ee isolates were more 
likely to contain DHPS mutations than other ITS haplotypes.
(147)
 
 
Sporadic single nucleotide changes were presumed to be PCR-generated errors if 
they occurred only once and in only one clone from a specimen. By ignoring these 
sporadic nucleotide additions, deletions and substitutions in the cloned sequences, 
novel ITS types may have been overlooked in this study. However, a strict 
approach to ITS classification was applied in order to minimize further 
complications in the field of ITS typing. Minor base changes were ignored in a 
clone if most of the clones from the specimen were 100 percent similar to a 
common, accepted ITS type. The usual associations between ITS1 and ITS2 types 
were considered during the analysis. In addition, the frequencies of previously 
reported ITS haplotypes were taken into consideration, with less frequent 
haplotypes being more likely to be recombinants. The occurence of PCR-
generated recombinants was minimized by using the modifications suggested by 
Beser et al .
(114)
 The primer concentration was increased two-fold in the first PCR 
reaction and five-fold in the second PCR reaction, and the time for the elongation 
step was increased during PCR cycling. We have chosen to report all ITS type 
combinations, but have marked those that could be artifacts, either PCR-generated 
or naturally occuring in the population. 
 
The frequency of multiple ITS haplotype infections in patients from this study 
was 48%, which made cloning of PCR products prior to sequencing essential. 
Some studies of ITS typing have employed only direct sequencing of PCR 
products without cloning, despite the fact that Lu et al 
(110)
 warned that this will 
not work for specimens with mixed ITS haplotypes. Direct sequencing of ITS 
PCR products can be performed on specimens containing unambiguous sequences 
i.e. those with a single P. jirovecii ITS haplotype. However, when specimens 
contain more than one type of P. jirovecii, a mixture of sequences are obtained 
and interpretation of ITS haplotypes is hampered. Thus cloning of PCR products 
prior to sequencing is required. By sequencing multiple clones it is possible to 
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detect multiple infections within the same specimen, as well as strains present in 
lower concentrations.  
 
6.4 Conclusions 
A total of 11 different bona fide ITS haplotypes, six ITS1 and nine ITS2 types, 
were found in P. jirovecii isolated from 40 HIV-positive patients. There were no 
obvious associations between ITS haplotype and a particular clinical characteristic 
or outcome. Almost half of the patients were infected with more than one 
P. jirovecii strain. Eg occurred at a high frequency of 85% among P. jirovecii 
infecting patients. The presence of the local South African haplotype Eu was 
confirmed. Other ITS haplotypes detected were: Em, Ec, Eb, Bi, Gg, Ep, Fu4, Ne 
and Ai. Two novel ITS1 sequences SA1 and SA2 were detected and are likely 
variations of type E. Eg haplotypes were more often associated with a wild-type 
DHPS genotype. The following ITS haplotypes had possible associations with a 
particular DHPS genotype: Eb with M2, Bi with M3, and Gg with M3.  
 
More studies from South Africa and the African continent are needed to 
characterize and understand the molecular epidemiology of P. jirovecii. 
Specimens from non-HIV immunocompromised patients with PCP should be 
included in future investigations. A single, standardized ITS typing system is 
required with simple names for the different ITS haplotypes. An alternative typing 
system for Pneumocystis using multilocus genotyping has shown promise and 
may be cheaper and less labour-intensive than ITS typing by cloning and 
sequencing. 
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Table 6.1 Frequency of P. jirovecii ITS haplotypes isolated from 40 HIV-positive 
patients with PCP in South Africa 
ITS haplotype No. of patients (%) 
n = 40 
No. of patients with a single 
ITS haplotype infection (%) 
Eg 34 (85) 17 (43) 
Eu 5 (13) 1 
(140)
 
Em 4 (10) 0 
Ec 4 (10) 1 
(140)
 
Eb 4 (10) 1 
(140)
 
Bi 3 (8) 0 
Gg 3 (8) 1 
(140)
 
Ep 3 (8) 0 
Fu4 2 (5) 0 
Ei
1
 2 (5) 0 
Ne 1 
(140)
 0 
Ai 1 
(140)
 0 
SA1
b
g 1 
(140)
 0 
SA2
b
g 1 
(140)
 0 
Au
a
 1 
(140)
 0 
Eu4
a
 1 
(140)
 0 
Fe
a
 1 
(140)
 0 
Ee
a
 1 
(140)
 0 
Ng
a
 1 
(140)
 0 
Cg
a
 1 
(140)
 0 
a 
Possible artifactual haplotype 
b 
Novel ITS1 E variants, GenBank accession numbers JN387046 and JN387047 
ITS2 type u reported by Robberts et al,
(118)
 GenBank accession number 
AY328054 
ITS2 type u4 reported by Hosoya et al 
(121)
 
ITS2 type p GenBank accession number AF013836 
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Table 6.2 Description of P. jirovecii ITS haplotypes and corresponding DHPS 
genotype in specimens from 40 HIV-positive patients with PCP 
Patient ITS haplotype (no. of clones) DHPS genotype
a
 
1 Eb (11); Eg (1) M2 + WT 
2 Eg (11) WT 
3 Ai (6); Eg 
(140)
; Eu (2); Au
b
 (1) WT 
4 Eg (11) M3 + WT 
5 SA1
d
g (8); Eg (4) WT 
6 Eg (12) WT 
7 Eg (5); Ec (2); Bi (2) M2 + WT 
8 Fu4 (6); Ec 
(140)
; Eu4
b
 
(140)
 WT 
9 Eg (11) M2 + WT 
10 Eg (8); Ec (2); Em (1); Eu (1) M3 + WT 
11 Eg (8); Eu 
(140)
 M3 + M2 + WT 
12 Eg (10) M2 
13 Eb (5); Fu4 
(140)
; Eg (2); Fe
c
 (1); Ee
c
 (1) M2 + WT 
14 Em (10); Eg (2) M3 + M1 
15 Ec (11) M2 + WT 
16 Eg (12) WT 
17 Gg (12) M3 
18 Eg (8); Em (4) WT 
19 Eg (10) M2 
20 Eg (8); Ne (1); Ep (1); Ng
b
 (2) M2 + WT 
21 Eb (8); Ep 
(140)
; Eg (1) M2 + M3 + WT 
22 Eg (10) M2 + M3 + WT 
23 Eg (12) WT 
24 Eg (9); Eu 
(140)
 WT 
25 Eg (9); Gg 
(140)
 WT 
26 SA2
d
g (10); Gg (2) M2 + WT 
27 Eg (12) M2 
28 Eu (12) M2 
29 Eg (6); Bi (1); Cg
b
 (1); Ei
b
 
(140)
 WT 
30 Eg (12) M3 
31 Eg (10); Em (1) M1 +M2 + M3 
32 Eb (12) M2 + WT 
33 Eg (12) WT 
34 Eg (12) WT 
35 Bi (8); Eg (2); Ei
b
 (2) M3 
36 Eg (11) WT 
37 Eg (9); Ep (1) WT 
38 Eg (12) M1 + WT 
39 Eg (12) M3 
40 Eg (12) WT 
a 
Mixtures of DHPS genotypes were resolved by cloning and sequencing 
b 
Possible artifactual haplotype 
c 
possible recombinant with a hidden Ne 
d 
novel ITS1 E variants, GenBank accession numbers JN387046 and JN387047  
 83 
Table 6.3 Prevalence of DHPS genotype with corresponding ITS haplotype in 
specimens from 30 HIV-positive patients with PCP 
ITS haplotype + DHPS genotype DHPS genotype 
prevalence (%) 
Eg + WT 26  (70) 
Eg + M2 5  (14)
a
 
Eg + M3 5  (14)
a
 
Eg + M1 1  
(140)
 
  
Eu + WT 2  (67) 
Eu + M2 1  (33) 
  
Eb + WT 1  (50)
a
 
Eb + M2 1  (50)
b
 
  
Ec + WT 2  (67) 
Ec + M2 1  (33) 
  
Em + WT 1  (100) 
  
Bi + WT 1  (50)
a
 
Bi + M3 1  (50)
b
 
  
Gg + WT 1  (50)
a
 
Gg + M3 1  (50)
b
 
  
Ep + WT 1  (100) 
  
Fu4 + WT 1  (100) 
  
Ai + WT 1  (100) 
  
SA1
c
g + WT 1  (100) 
 a 
Lower than expected prevalence of DHPS genotype. Expected  
genotype prevalence: WT 73%, M2 27%, M3 20%, M1 3% 
b 
Higher than expected prevalence of DHPS genotype  
c 
Novel ITS1 E variant, GenBank accession number JN387046 
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Table 6.4 Patient demographics and clinical details of 40 HIV-positive patients according to ITS haplotypes 
Characteristic All 
Single ITS haplotype infections 
Eg Eu Ec Eb Gg 
Number of patients (%) 40 17 (43) 1 
(140)
 1 
(140)
 1 
(140)
 1 
(140)
 
Gender: Female, No. of patients (%) 32 (80) 14 (82) 1 1 1 1 
Mean age, years ±SD (range) 34±10 (20-56) 36±11 (20-56) 40 56 30 29 
Median CD4
+
 cell count, cells/mm
3
 (range) 35 (2-175) 27 (2-106) 5 U 29 44 
Newly diagnosed with HIV on admission, No. of patients (%) 26 (65) 10 (59) 1 U 0 0 
History of previous PCP, No. of patients (%) 3 (8) 1 (6) 0 0 0 1 
Median hospital stay, days (range) 10 (2-38) 10 (2-38) 22 5 8 18 
Mechanical ventilation necessary, No. of patients (%) 2 (5) 1 (6) 0 0 0 0 
Respiratory failure, No. of patients (%) 33 (83) 14 (82) 1 1 0 1 
Outcome:       
Death in hospital, No. of patients (%) 10 (25) 5 (29) 1 1 0 0 
Discharged, No. of patients (%) 30 (75) 12 (71) 0 0 1 1 
     Discharged, alive after 3 months, No. of patients (%) 14 (47) 3 (25)   1 1 
Discharged, death within 3 months, No. of patients (%) 3 (10) 3 (25)   0 0 
     3-month outcome unknown, No. of patients (%) 13 (43) 6 (50)   0 0 
U unknown 
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                      10        20        30        40        50        60        70        80                
 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ITS1 E  GAAAATTCAGCTTAAACACTTCCCTAGTGTTTTAGCATTTTTCAAACATCTGTGAATTTTTTTTTTGTTTGGCGAGGAGC  
SA2  clone 1 .................................................................-..............  
SA2  clone 2 ................................................................................  
SA2  clone 3 ................................................................................  
SA2  clone 4 ................................................................................  
SA2  clone 6 ................................................................................  
SA2  clone 7 ................................................................................  
SA2  clone 8 .................................................................-..............  
SA2  clone 10................................................................................  
SA2  clone 11................................................................................  
SA2  clone 12................................................................................  
          ↑ 
                      90       100       110       120       130       140       150              
 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.. 
ITS1 E  TGGCTTTTTTGCTTGCCTCGCCAAAGGTGTTTATTTTTAAAATTTTAAATTGAATTTCAGTTTT-AGAATTTTTTAA  
SA2  clone 1 ................................--..............................T............  
SA2  clone 2 ................................--..............................T............  
SA2  clone 3 ................................--..............................T............  
SA2  clone 4 ................................--..............................T............  
SA2  clone 6 ................................--........C.....................T............  
SA2  clone 7 ................................--..............................T............  
SA2  clone 8 ................................--..............................T............  
SA2  clone 10................................--...................G..........T............  
SA2  clone 11................................--..............................T............  
SA2  clone 12................................--..............................T............  
                                                              ↑                  ↑ 
Figure 6.2 The novel ITS1 sequence SA2 identified in ten clones of P. jirovecii isolated from a single PCP patient in South Africa. The 
sequence of SA2 is shown aligned with ITS1 type E, which exhibited the closest homology among established ITS1 types. 
Sequence E (AF013810) was originally described by Lee et al 
(112)
 
. nucleotide identical to E sequence 
- gaps in sequences, ↑ sporadic polymorphisms presumed to be PCR-generated errors 
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 10        20        30        40        50        60        70        80                
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ITS1 E GAAAATTCAGCTTAAA-CACTTCCCTAGTGTTTTAGCATTTTTCAAACATCTGTGAATTTTTTTTTTGTTTGGCGAGGAG  
SA1 clone 1 ................A...............................................................  
SA1 clone 4 ................A.................................................-.............  
SA1 clone 5 ................A.................................................-.............  
SA1 clone 6 ................A.................................................-.............  
SA1 clone 8 ................A.................................................-.............  
SA1 clone 9 .G..............A.................................................-.............  
SA1 clone 10 ................A.................................................-.............  
SA1 clone 11 ................A.................................................-.............  
             ↑               ↑ 
 90       100       110       120       130       140       150              
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.. 
ITS1 E CTGGCTTTTTTGCTTGCCTCGCCAAAGGTGTTTATTTTTAAAATTTTAAATTGAATTTCAGTTTTAGAATTTTTTAA  
SA1 clone 1 .............................................................................  
SA1 clone 4 .............................................................................  
SA1 clone 5 .............................................................................  
SA1 clone 6 .............................................................................  
SA1 clone 8 .............................................................................  
SA1 clone 9 .............................................................................  
SA1 clone 10 .............................................................................  
SA1 clone 11 .............................................................................  
 
Figure 6.3 The novel ITS1 sequence SA1 identified in eight clones of P. jirovecii isolated from a single PCP patient in South Africa. The 
sequence of SA1 is shown aligned with ITS1 type E, which exhibited the closest homology among established ITS1 types. 
Sequence E (AF013810) was originally described by Lee et al 
(112)
 
. nucleotide identical to E sequence 
- gaps in sequences, ↑ sporadic polymorphisms presumed to be PCR-generated errors 
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C H A P T E R   S E V E N 
 
GENERAL DISCUSSION AND CONCLUSIONS 
 
The purpose of this research was to investigate the prevalence of P. jirovecii 
strains containing DHPS mutations in South Africa, and to ascertain their clinical 
significance in HIV-positive patients with Pneumocystis pneumonia. The 
molecular epidemiology of P. jirovecii was explored by characterizing the strains 
circulating in HIV-infected patients. 
 
7.1 Prevalence of DHPS Polymorphisms in South Africa 
An increased prevalence of P. jirovecii with point mutations in the fas gene, 
which codes for the DHPS enzyme, has been associated with the use of 
sulfonamides. This awoke concern for possible drug resistance in fungal strains. 
The pilot study, which non-randomly screened P. jirovecii-positive specimens 
from 65 patients from four different provinces in South Africa, confirmed the 
presence of DHPS polymorphisms in 42% of these specimens (Chapter Three). 
This is one of the first studies from South Africa investigating DHPS mutations in 
P. jirovecii organisms. Two other studies from South Africa with smaller sample 
sizes were published after the pilot study results were analyzed. They reported 
much lower prevalences of DHPS mutations, 13% and 4% respectively.
(101-102)
 
 
Based on the results of the pilot study (Chapter Three), a decision was taken to 
proceed with a large prevalence study investigating DHPS polymorphisms in the 
general P. jirovecii population (Chapter Four), as well as a clinical study to 
ascertain their potential significance in patients with PCP (Chapter Five). The 
prevalence study was conducted over one year, and the number of screened 
specimens and patients (n = 712) makes this study the largest of its kind 
conducted to date in the developing world. P. jirovecii infection was confirmed by 
IF microscopy in 24% of patients with suspected PCP. Colonization by the 
fungus, characterized by IF-negative microscopy and low gene copy numbers in 
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the real-time PCR, occurred in 17% of patients. The prevalence of infections with 
P. jirovecii containing DHPS mutations in adult South African patients was high 
at 56%, and these results confirmed the findings of the pilot study. There were no 
significant differences in the proportions of wild-type or mutant DHPS genotypes 
between genders, age groups or patients from distinct geographical locations. 
Studies from the USA generally report the highest prevalences of P. jirovecii 
DHPS mutations, whilst European countries have much lower prevalences (Figure 
1.5). The few studies performed in developing countries have all reported low 
prevalences of P. jirovecii containing DHPS mutations (Table 1.3). 
 
The clinical study is unique in the developing world as it was conducted 
prospectively and had a large sample size, especially in the mutant DHPS 
category (Chapter Five). The majority of patients (61%) harboured mutant 
P. jirovecii strains, a result which is consistent with the 56% reported from the 
prevalence study. The proportion of mutant DHPS genotypes stayed relatively 
stable over the study period. Multiple P. jirovecii infections were found in 47% of 
patients, compared with 21% in the prevalence study. Figure 7.1 illustrates a 
comparison of the prevalence of P. jirovecii DHPS mutations from the pilot, 
prevalence and clinical studies. 
 
A comparison of the proportions of P. jirovecii DHPS mutant genotypes from the 
pilot, prevalence and clinical studies is presented in Figure 7.2. M1 was the most 
common mutant DHPS genotype in the pilot study, whilst the different mutant 
genotypes had similar frequencies in the prevalence study. The M2 genotype was 
most frequent in the clinical study, followed by the M3 genotype. P. jirovecii 
strains containing single DHPS mutations, either M1 or M2, were present at 
similar frequencies in all three studies at an average of 29%. The double mutant 
M3 genotype was most prevalent in P. jirovecii infecting clinical study patients 
(25% clinical study versus 12% prevalence study versus 8% pilot study). The 
median frequency of the M3 genotype from all three studies was 12%. P. jirovecii 
infections with more than one DHPS genotype were detected in 47% of patients 
from the clinical study, 21% from the prevalence study and 14% from the pilot 
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study.These apparent differences in the frequencies of DHPS mutant genotypes 
could be explained by different sample populations with local variations in 
genotype frequencies. The prevalence study had a large sample size from 
hospitals in six provinces, whilst the clinical study was conducted at a single large 
hospital in Gauteng Province. Another factor that could affect the distribution of 
genotypes is the lack of resolution of mixed genotypes in 36% of specimens from 
the prevalence study. Specimens from the clinical study with mixed ambiguous 
genotypes were cloned and sequenced to resolve the individual genotypes.  
 
7.2 Clinical Significance of DHPS polymorphisms 
The in-hospital mortality was higher than the mortality of the discharged patients 
at 3 months (21% versus 15%). Significantly more patients died in hospital of 
P. jirovecii containing mutant DHPS genotypes than those infected with wild-type 
strains (26% versus 8%, P = 0.04). Our study is one of the few to show an 
association between mutant DHPS genotypes and increased in-hospital mortality.  
A study from Italy with a low prevalence of mutant genotypes also showed a 
correlation between DHPS mutants and worse outcomes.
(92)
 Crothers et al 
(87)
 
found a trend for patients with mutant strains to have worse outcomes than those 
with wild-type P. jirovecii. Helweg-Larsen et al 
(67)
 found that the presence of 
DHPS mutations was the most important predictor of mortality. 
 
Mortality at 3 months among the discharged patients was associated with the 
wild-type DHPS genotype. However, cause of death in these patients was 
unknown. There were no significant associations in patients harbouring 
P. jirovecii with single DHPS mutations (genotypes M1 and M2) compared with 
those infected with the double mutant M3 genotype. However, there was an 
insignificant trend for patients infected with the M3 genotype to have a lower 
median CD4
+
 cell count compared to patients harbouring strains with single 
mutations (P = 0.06).  
 
There were no significant associations between the presence of DHPS mutant 
genotypes and previous PCP or exposure to sulfa medication. However, very few 
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patients reported a previous PCP episode and only 16% of patients had been 
exposed to any sulfa-based medication in the 4 months prior to admission. Almost 
60% of the patients diagnosed with HIV on admission harboured P. jirovecii with 
mutant DHPS genotypes. Inter-human transmission of P. jirovecii carrying mutant 
DHPS genotypes could, at least in part, explain the high prevalence of DHPS 
mutations in adult HIV-positive South Africans. 
 
7.3 Strain Characterization of P. jirovecii 
The P. jirovecii strains present in respiratory specimens from a subset of patients 
enrolled in the prospective clinical study were characterized by ITS typing.  
A total of 11 different bona fide ITS haplotypes, six ITS1 and nine ITS2 types, 
were found in P. jirovecii isolated from 40 HIV-positive patients. There were no 
obvious associations between ITS haplotype and a particular clinical characteristic 
or outcome. Almost half of the patients were infected with more than one 
P. jirovecii strain. The global ITS haplotype Eg occurred at a high frequency of 
85% among P. jirovecii infecting patients. The presence of the local South 
African haplotype Eu was confirmed, and it was the second most common ITS 
haplotype. Other ITS haplotypes detected were: Em, Ec, Eb, Bi, Gg, Ep, Fu4, Ne 
and Ai. Fu4 and Ep had previously only been reported in Japan. Two novel ITS1 
sequences SA1 and SA2 were detected and are likely variations of type E.  
 
The prevalence of mutant DHPS P. jirovecii strains among this group of patients 
was 60%, and the most frequent DHPS mutant genotype was M2. The Eg 
haplotype was most often associated with a wild-type DHPS genotype. The 
following ITS haplotypes had possible associations with a particular DHPS 
genotype: Eb with M2, Bi with M3, and Gg with M3.  
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7.4 Concluding Remarks 
The prevalence of P. jirovecii strains containing DHPS polymorphisms among 
adult HIV-positive South Africans is high. A third of patients were infected with 
P. jirovecii strains containing single DHPS mutations and 12% contained the 
double mutant M3 genotype. Inter-human transmission of P. jirovecii carrying 
mutant DHPS genotypes could explain, at least in part, this high prevalence. 
 
Significantly more patients died in hospital of P. jirovecii containing mutant 
DHPS genotypes than those infected with wild-type strains. This finding has 
potentially grave consequences in the light of the high prevalence of DHPS 
mutations in the general P. jirovecii population. 
 
A limited number of P. jirovecii strains, characterized by ITS typing, defines the 
diversity in South Africa. More studies from South Africa and the African 
continent are needed to characterize and understand the molecular epidemiology 
of P. jirovecii. Specimens from non-HIV immunocompromised patients with PCP 
should be included in future investigations. 
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Figure 7.1 A comparison of the prevalence of P. jirovecii DHPS mutations from 
the pilot, prevalence and clinical studies (Chapters Three, Four and 
Five) 
 
 
Figure 7.2 A comparison of the proportion of P. jirovecii mutant DHPS 
genotypes from the pilot, prevalence and clinical studies (Chapters 
Three, Four and Five) 
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8.   A P P E N D I C E S   A   T O   H 
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APPENDIX A 
PCP Study, Clinician’s Clinical Case Report Form 
 
STUDY NO: ______________ 
 
HIV status:  pos  neg    declined to be tested  
Date of first positive HIV test: ____________________ 
 
Previous PCP: no  yes  If yes, date: _______________ 
Previous pneumonia or RTI: no  yes  If yes, date: _______________ 
Bactrim prophylaxis in last 3 mo: no  yes  If yes, dose: ______________ 
 
HAART:  no  yes  If yes, date started: ___________________ 
Drugs and dose:   d4T/stavudine/Zerit _______________________ 
   3TC/lamivudine__________________________ 
   efavirenz/Stocrin _________________________ 
   nevirapine/Viramune ______________________ 
   zidovudine/AZT __________________________ 
   ddI/Videx _______________________________ 
   lopinavir + ritonavir/Kaletra _________________ 
     
Previous TB:  no  yes    If yes, when? _____________ 
Previous medical/surgical history: __________________________________ 
______________________________________________________________ 
______________________________________________________________ 
______________________________________________________________ 
 
Medication in last 3 mo:___________________________________________ 
 
_______________________________________________________________ 
_______________________________________________________________ 
 
 
Smoker:  no  yes  
 
 
SYMPTOMS 
Dyspnoea:  no  yes   If yes, duration: ______________________ 
 
Cough:  no   yes   Productive   Non-productive    Duration: _______ 
 
Fever:  no  yes  If yes, duration: __________________ 
 
Chest pain:  no  yes        Right   Left  Duration: ___________ 
 
 95 
STUDY NO: ______________ 
 
EXAMINATION: 
 
Temp: ______________ 
 
BP: ________________ 
 
Pulse: ______________ 
 
RR: ________________ 
 
Oral thrush :      yes     no 
 
Chest auscultation: 
______________________________________________________________ 
 
______________________________________________________________ 
 
 
 
Other significant clinical findings : 
 
______________________________________________________________ 
 
______________________________________________________________ 
 
 
______________________________________________________________ 
 
______________________________________________________________ 
 
 
______________________________________________________________ 
 
______________________________________________________________ 
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STUDY NO: ______________ 
 
INVESTIGATIONS 
 
Blood investigations: 
 Date Result 
FBC   
U&E   
CD4   
   
   
   
   
   
   
   
   
 
ABG: Date: _______________  FiO2 __________ 
 pH ___________  HCO3 __________ 
 pCO2 _________  BE ___________  
 pO2 __________  sat ___________ 
 
CXR: Date: _____________  No. _______________ 
 
______________________________________________________________ 
 
______________________________________________________________ 
 
Sputum: 
 Date Result 
MC&S 
 
  
TB auramine 
 
  
TB culture 
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STUDY NO: ______________ 
 
Investigations for PCP: 
e.g. sputum, induced sputum, bronchial washings, BAL, transbronchial biopsy: 
Specimen Date Result 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
If induced sputum was performed:   by wall O2  by portable nebulizer  
 
TREATMENT 
 
O2:   24%      28%       35%   40%       60%        polymask  
 
Co-trimoxazole: 
Route Dose Start date End date 
    
    
    
      
Steroids: 
Route Dose Start date End date 
    
    
    
 
Other drugs: 
Route Dose Start date End date 
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DAILY PROGRESS 
 
Day Date Temp BP Pulse RR O2 sat on 
room air 
O2 sat on 
oxygen (%) 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 
 
 
COMPLICATIONS 
Respiratory failure: no  yes  
 
Pneumothorax:  no  Yes        Spontaneous  Iatrogenic  
Right      Left        Date: _________ 
    Rx:   O2       Heimlich valve    IC drain   
 
Sulpha allergy: no  yes  
 
Other: 
______________________________________________________________ 
 
______________________________________________________________ 
 
______________________________________________________________ 
 
______________________________________________________________ 
 
 
OUTCOME 
 
Discharged   Date: ________  Follow-up appointment: _________ 
    
Died   Date: ____________ 
 
Excluded    Date: ____________ 
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APPENDIX B 
PCP Study Nurse’s Clinical Case Report Form 
 
Informed consent obtained: yes  no  
If yes, check that a study number has been assigned to this patient and proceed 
with the interview. 
 
STUDY NO: ___________    
 
Interviewer’s name:____________________ 
 
Date of admission:____________________ 
 
Ward:_______________ 
 
Patient’s name:______________________________________ 
 
Age: ____________ 
 
Gender: M   F  
 
Hospital no:________________________ 
 
Weight: ________ 
 
Height: ________ 
 
Address: 
____________________________________________________________ 
 
____________________________________________________________ 
Telephone no:________________ 
 
 
Leigh Dini will detach this page once the form is complete and keep it secure. 
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STUDY NO: ___________ 
 
HIV status:  pos  neg      declined to be tested  
Date of first positive HIV test: ____________________ 
 
Previous PCP:   no  yes  If yes, date: _______________ 
Previous pneumonia or RTI: no  yes  If yes, date: _______________ 
Bactrim prophylaxis in last 3 mo: no  yes   If yes, dose: ______________ 
 
HAART:  no  yes  If yes, date started: ____________________ 
 Drugs and dose:   
 d4T/stavudine/Zerit ____________________________  
  3TC/lamivudine________________________________ 
  efavirenz/Stocrin ______________________________ 
  nevirapine/Viramune ___________________________ 
  zidovudine/AZT _______________________________ 
  ddI/Videx ____________________________________ 
  lopinavir + ritonavir/Kaletra ______________________ 
     
Previous TB:  no  yes    If yes, when? _______________ 
 
Previous medical/surgical history: ____________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
Medication in last 3 mo:____________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
Smoker:  no  yes  
 
 
SYMPTOMS 
Dyspnoea:  no  yes   If yes, duration: _________________ 
Cough:  no  yes  Productive  Non-productive  Duration: _______ 
Fever: no  yes  If yes, duration: ____________________________ 
Chest pain:  no  yes        Right    Left  Duration: _________ 
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STUDY NO: ______________ 
 
Investigations for PCP: 
e.g. sputum, induced sputum, bronchial washings, BAL, transbronchial biopsy: 
Specimen Date Result 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
If induced sputum was performed:   by wall O2  by portable nebulizer  
 
DAILY PROGRESS 
Day Date Temp BP Pulse RR O2 sat on 
room air 
O2 sat on 
oxygen (%) 
        
        
        
        
        
        
        
        
        
        
        
 
 
OUTCOME 
 
Discharged         Date: __________   Follow-up appointment: __________ 
    
Died   Date: ____________ 
 
Excluded    Date: ____________ 
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APPENDIX C 
PCP Study, Telephonic Questionnaire 
 
Patient name:_________________ Date discharged:______________  
 
Months after discharge:___________STUDY NO: ___________ 
 
This form is to be completed about 4 months after a patient with PcP has been 
discharged from hospital 
 
Name of interviewer:______________________________________ 
 
Introduction: Introduce yourself and explain why you are calling and that you would like 
to ask a few questions about the patient’s health and the medications they are taking.   
 Date Telephone 
number called 
Reached 
someone?  
Name of 
person reached 
Relationship 
to patient  
1
st
 attempt 
 
    Yes No   
2
nd
 attempt 
 
  Yes No   
3
rd
 attempt 
 
  Yes No   
(if you can’t make contact after 3rd attempt please record the patient as lost to follow-up) 
 
Please complete the form once you’ve made contact with the patient or secondary contact 
1. Are you speaking to the participant directly?................................................ 
0=No  1=Yes                         
(If yes: cross through questions 2 through 9 and skip to question 10) 
 
If you are speaking to the secondary contact:  (explain that the participant is part of a research 
study and that you would like to contact him or her) 
2. Is there a phone number to reach the participant directly?.............................. 
0=No  1=Yes 
3. What is that number?........................................................... 
(If number is provided: please call the patient and complete the questionnaire starting 
with question 10. If the number is not provided: please ask the contact questions 4-9) 
 
If the contact number for the participant is not provided, then ask the following questions 
4. How is the participant’s general health status? 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
 
5. Is the participant still alive? ……….……………………………………………. 
0=No  1=Yes                        2=Not sure/don’t know 
(If yes: the form is completed.  Thank the contact for their help. 
If no:  ask questions 6-9) 
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If the participant has died 
6. Approximately when did the participant pass away?................// 
7. Where did the participant pass away?......................................................................... 
1=At home               2=Hospital              3=Hospice                  4=Other 
If other specify_______________________________________________________________________________ 
 
8. Did the participant have pneumonia when he or she passed away? …………… 
0=No  1=Yes                        2=Not sure/don’t know 
 
 
9. Can you tell me more about how he or she passed away? 
_____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
If you’ve answered this question:  the form is completed.  Please thank the contact for 
their help. 
 
If you are speaking to the participant directly 
 
10. How is your health generally? 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
 
11. Have you had any health problems since your discharge from Chris-Hani 
Baragwanath Hospital?........................................................................................ 
0=No  1=Yes                        2=Not sure/don’t know  
(If no: skip to question 13) 
12. Tell me more about the health problems you have had 
_______________________________________________________________________ 
_______________________________________________________________________ 
 
13. Have you had pneumonia since you were discharged?…………....………...…....... 
0=No  1=Yes                2=Don’t know/Not sure 
14. Have you had PcP since you were discharged? ……….......……………...…........... 
0=No  1=Yes                2=Don’t know/Not sure 
15. Are you taking Bactrim (also called Nucotrim) drugs at the moment?...................... 
0=No  1=Yes                        2=Not sure/don’t know  
16. Have you had TB since you were discharged?........................................................... 
0=No  1=Yes                        2=Not sure/don’t know  
17. Have you been given ART (antiretroviral) drugs?..................................................... 
0=No  1=Yes                        2=Not sure/don’t know  
 
Thank you for answering my questions and I appreciate your time. 
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APPENDIX D 
 
PCP Study, Postal Questionnaire 
 
 
Hello, my name is Doctor Michelle Wong from Chris Hani Baragwanath 
Hospital.  I am trying to find one of patients that I treated for a respiratory illness.  
Please can you help me to find this patient by answering a few questions?  
 
My patient’s name is:  type in patient’s name. 
 
1. Do you know my patient? Yes     No     
   
2. Do you have a contact telephone number for my patient? Yes     No    
If yes, please write the telephone number here:______________________ 
 
3. Do you have an address for my patient?     Yes     No    
If yes, please write the address here:______________________________ 
___________________________________________________________ 
 
4. Do you know if my patient is alive  ,  has passed away       or unknown ? 
        If he/she has passed away, do you know the date of death? _____________ 
 
 
Please could you send this form back to me in the enclosed envelope (I have 
already paid for the postage)? 
 
 
Thank you very much for helping me. 
 
Best regards 
 
Dr Michelle Wong and Enrolled nurse Prudence Seboka 
(Tel. 011 933 9168) 
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